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Chapter 1
General introduction and outline of the thesis
8Prostate cancer is the most frequently diagnosed cancer in men from developed 
countries, with an annual estimated 1.1 million new cases worldwide.1 Moreover, 
it is the fifth leading cause of cancer related deaths, with around 307.000 cases 
yearly. 
Most often prostate cancer does not present with clinical symptoms, and current 
diagnosis is prompted by prostate specific antigen (PSA) testing and/or digital 
rectal examination. However, PSA is an organ specific biomarker and not a cancer 
specific biomarker. Therefore, various non-malignant conditions can cause a 
rise in PSA blood levels (e.g. prostatitis, benign prostatic hyperplasia). Despite 
the low specificity of PSA for the detection of prostate cancer, this serum-based 
biomarker is currently still the standard of care in prostate cancer diagnosis. An 
increased PSA level is still the most commonly used argument to opt for transrectal 
ultrasound guided prostate biopsies. However, the procedure of taking prostate 
biopsies is an invasive procedure with considerable risk of complications (e.g. 
infection, bleeding, urine retention).2 Moreover, a substantial number of patients 
undergoing prostate biopsies do not have prostate cancer or are diagnosed with 
low-grade prostate cancer (Gleason score <7). Approximately 42% of the detected 
cancers are low-grade tumours and might not have become clinically significant 
during lifetime.3 Since these patients do not benefit from active treatment, they 
are subject to overdiagnosis. Besides the fact that this might cause a psychological 
burden to these patients, it leads to unnecessary treatment, exposure to potential 
side effects and increasing healthcare costs.3 
A large European Randomized Study of Screening for Prostate Cancer (ERSPC) 
assessed PSA testing in 162.243 men between 55 and 69 years of age and it was 
demonstrated that to prevent one prostate cancer death at 13 years follow-up, 
781 men needed to be invited for screening and 27 cancers needed to be 
detected.4 Despite the fact that prostate cancer mortality can be reduced by 
population-based screening, it remains controversial due to the earlier mentioned 
limitations of PSA based screening.
Therefore, the main objective in prostate cancer diagnostics is to improve the 
accuracy of detection and distinguish indolent, insignificant prostate cancer 
from aggressive, significant disease that needs treatment. Recent technological 
improvement led to substantial progress in the field of molecular profiling and 
biomarker detection techniques. This resulted in the discovery of novel promising 
biomarkers that can potentially contribute to this objective. These molecular 
biomarkers for prostate cancer can be measured in various human substrates, 
e.g. urine, blood and tissue. 
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Tissue samples can be of use mostly for prognostic purposes once an invasive 
procedure has been performed. Blood, on the contrary, can be obtained in a less 
invasive manner and might contain valuable molecular information for diagnostic, 
prognostic and predictive purposes. Urine is the least invasive substrate to 
obtain and given the anatomical localization of the prostate and its relation to 
the urethra, this substrate can be of value to obtain molecular information that 
represents biochemical processes within the prostate. This might therefore be the 
substrate of choice for diagnostic and prognostic biomarker testing.
These substrates and molecular biomarker detection techniques have been 
subjected to extensive research in the last decade and have led to a significant 
increase in knowledge about biological tumour behaviour. Despite these 
improvements, further improvements in diagnostic and prognostic tools for 
prostate cancer are needed. The studies described in this thesis have contributed 
to this improvement in the field of prostate cancer diagnostics and might function 
as the basis for future research.
OUTLINE OF THE THESIS
In this thesis the hypothesis is tested that urine biomarkers can function as a 
reliable diagnostic and prognostic tool in men at risk for prostate cancer and 
that blood biomarkers can serve as predictive and surrogate endpoint markers in 
castration-resistant prostate cancer patients. 
Chapter 2 provides a more extensive introduction and a critical overview of 
the current clinical use of novel urine-, blood- and tissue-based biomarkers in 
prostate cancer. It describes the current clinical use of PSA, the identification 
and clinical validation of PCA3 and TMPRSS2-ERG and a range of other promising 
novel prostate cancer biomarkers and biomarker substrates.
Urine is a complex substrate that can be separated into various fractions, by 
centrifugation and filtration. The exosomal fraction comprises small tissue 
derived vesicles that contain a wide variety of proteins and RNA that can reflect 
their tissue of origin. In chapter 3 we evaluated the expression of PCA3 and 
TMPRSS2-ERG messenger RNA as prostate cancer specific biomarkers, and KLK3 
messenger RNA as prostate specific reference gene, in first-catch urine exosomes 
and sediments of 30 patients. Furthermore, we assessed the impact of a digital 
rectal examination on the biomarker levels. 
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Prostate cancer is a heterogeneous disease with each tumour displaying its 
own characteristics. The use of a biomarker panel, especially in combination 
with approved clinical risk factors within a multivariable prediction model, can 
potentially contribute to improve prostate cancer diagnosis and might be able 
to facilitate risk stratification in clinical practice. In chapter 4 we present the 
results of a prospective multicenter study in 905 men demonstrating the clinical 
validation of a novel urinary molecular biomarker-based risk score to identify 
patients harbouring high-grade prostate cancer. 
In addition to this study, chapter 5 describes a decision analytical model to compare 
the quality of life and costs of this novel urinary molecular biomarker-based risk 
score with the current standard of care in men with PSA levels >3 ng/ml.  
Patients with advanced prostate cancer who undergo chemical or surgical 
castration will ultimately experience recurrence of disease. This stage is called 
castration-resistant prostate cancer (CRPC). The treatment options in the field of 
CRPC are rapidly evolving, however, the main issue in the management of CRPC 
is the lack of surrogate endpoints for treatment response and survival. Chapter 
6 describes an exploratory study in 20 patients demonstrating the feasibility to 
detect KLK3, PCA3 and TMPRSS2-ERG messenger RNA in the peripheral blood 
mononuclear cell fraction of CRPC patients. 
A general discussion and future perspectives based on this thesis can be found in 
chapter 7, followed by a summary in English and Dutch in chapter 8.
11
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INTRODUCTION
Prostate cancer (PCa) is the most common malignancy in men, with an annual 
estimated incidence of 382,000 new cases in Europe and 239,000 in the United 
States.1, 2 Incidence is highest in Western society and annual worldwide estimates 
for new PCa cases and deaths are 1.100.000 and 307.000, respectively.3 The 
tremendous increase of PCa incidence over the past decades can mainly be 
assigned to the widespread use of serum prostate specific antigen (PSA) testing, 
introduced in the late 1980s. 
PSA, a kallikrein serine protease encoded by the KLK3 gene, is secreted almost 
exclusively by the epithelial cells of the prostate. This biomarker is organ-specific 
and small quantities are present in blood serum of healthy men. However, PSA 
is not cancer-specific and various non-malignant conditions can cause a rise in 
PSA blood levels, e.g. benign prostatic hyperplasia and prostatitis. Despite its low 
specificity for the diagnosis of PCa upon prostate biopsies, PSA is currently, in 
combination with a digital rectal examination (DRE) and transrectal ultrasound 
(TRUS) guided prostate biopsies, the most commonly used diagnostic method for 
PCa. PSA is measured as a continuous parameter and therein also lies the pitfall. 
Although increased PSA levels are associated with a higher risk of harbouring PCa, 
there is no optimal threshold value for the presence of PCa. Moreover, a study by 
Thompson et al. demonstrated a risk of approximately 9% to have PCa, in men 
with a PSA ≤ 1.0 ng/mL.4 
The widespread use of PSA has led to an increase in diagnostic prostate biopsies, 
which in turn resulted in the diagnosis of more insignificant tumours. A fraction 
of these screen-detected tumours might not have become clinically significant 
during lifetime. Patients that have these tumours are therefore overdiagnosed, 
leading to unnecessary treatment, exposure to potential side effects, an increase 
in healthcare costs for the community and bringing psychological burden to the 
patient.5, 6 In a European screening study involving 182,160 men, the authors 
demonstrated that to prevent one PCa death at 13 years of follow-up, 781 men 
needed to be invited for screening and 27 cancers needed to be detected.7 
Therefore, PCa screening based on PSA levels remains controversial, despite the 
fact it reduces PCa mortality. 
This led in 2012 to the recommendation by the U.S. Preventive Services Task 
Force that men should not be screened with PSA. Recently, it was shown that the 
number of men with advanced PCa at diagnosis has been rising by 74%. This is 
likely due to the strong decline in random PSA testing and it strongly suggests that 
PSA based screening should be improved and not abandoned.8
Several PSA modifications have been described and evaluated in the attempt to 
improve diagnostic accuracy for early PCa detection and to use as a prognostic 
15
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tool in the follow-up of PCa patients. These derivatives include PSA density, PSA 
velocity and PSA doubling time, free/total PSA ratio and PSA isoforms. Although 
a study demonstrated that a lower percentage of free PSA was associated with 
a higher risk of PCa at biopsy in men who have total PSA levels between 4 and 
10 ng/mL, these results must be used with caution as several pre-analytical and 
clinical factors may influence this ratio.9, 10 PSA velocity and PSA doubling time 
are correlated with PCa diagnosis at biopsy, however, there is little evidence 
that both provide additional value to absolute total PSA level alone.11 There are 
different perspectives on the fact whether PSA kinetics can predict outcome in 
PCa patients, although it seems that PSA doubling time has a high sensitivity for 
predicting recurrence after radical prostatectomy and radiotherapy.12-14 
A specific PSA isoform called [-2]proenzyme PSA (p2PSA) and its derivatives; 
%p2PSA and the commercially available Beckman Coulter Prostate Health Index 
(phi: (p2PSA/free PSA) x √PSA) improve the predictive accuracy for PCa detection 
compared to total PSA and percentage free PSA.15, 16 In a study including 646 men, 
phi significantly outperformed total PSA (area under the curve [AUC] of 0.67 
versus 0.50, respectively) for the diagnosis of PCa upon initial biopsy.15 Another 
study assessed phi and PCA3 in an initial biopsy cohort consisting of 300 eligible 
men. Both phi and PCA3 were independent predictors of PCa and they showed 
comparable diagnostic performance (AUC 0.77 and 0.73, respectively).17 This 
diagnostic tool therefore might increase the ability to detect PCa and lower the 
rate of unnecessary biopsies. However, these findings have to be further validated 
before implementation in clinical practice. 
Another blood-based test that recently became available is the 4K score (OPKO 
Health, Inc.). This test combines the measurement of four prostate-specific 
kallikreins in blood with clinical information in an algorithm that calculates the 
probability of significant (Gleason score ≥7) PCa. This panel of four kallikrein 
proteins, including human kallikrein-related peptidase 2 (hK2), total, free and 
intact PSA, have been studied in blood samples of pre-biopsy patients in multiple 
cohorts. The four-kallikrein model was able to predict the biopsy outcome more 
accurately than total PSA and age alone.18 Parekh et al. showed in a cohort of 1012 
men scheduled for prostate biopsy a good diagnostic performance (AUC 0.82) 
of the 4K score in detecting significant PCa.19 A direct head-to-head comparison 
between the 4K score and phi demonstrated similarly improved discrimination 
when predicting prostate cancer and high-grade prostate cancer.20
To predict the potential risk of PCa of an individual patient, risk calculators 
might be useful. Risk calculators including several predictive factors to stratify 
patients for prostate biopsy have been developed. Two well known calculators 
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that are online available are the Prostate Cancer Prevention Trial (PCPT 2.0) and 
the European Randomised Study of Screening for PCa (ERSPC) risk calculators.21, 
22 The first includes PSA, DRE results, age, family history of PCa, ethnicity and 
prior biopsy. The latter includes PSA, DRE results, TRUS findings, prior biopsy and 
prostate volume. The use of risk calculators allows a more individual assessment 
of PCa risk and provides a better predictive accuracy compared to PSA alone.23
As a consequence of the limitations of the PSA test, together with improving 
technologies and knowledge of molecular biology, enormous progress has been 
made in the field of molecular profiling and biomarker detection techniques 
(mass spectrometry, high throughput screening, cell and tissue based microarrays 
etcetera). This resulted in the discovery of novel biomarkers which could 
potentially contribute to more accurate prediction of biological behaviour in a 
non-invasive way. An overview of the current commercially available biomarker 
tests for prostate cancer is displayed in Table 1.
NOVEL URINE-BASED PROSTATE CANCER BIOMARKERS
The definition of a biological marker (biomarker) has a broad prospect. In general, 
a biomarker can be defined as a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention.24 In order to make a 
biomarker an ideal marker for general use in PCa management, it should be able 
to differentiate tumour tissue from benign tissue, and aggressive tumours from 
insignificant tumours, with a high specificity and sensitivity. Furthermore, it should 
be a non-invasive test and be as inexpensive as possible to encourage widespread 
use. Present-day study designs with diagnostic accuracy as endpoint, need to be 
conducted in accordance with the Standards for Reporting of Diagnostic Accuracy 
criteria (STARD) in order to improve accuracy and completeness of these studies. 25
Biomarkers can be measured in several distinct substrates, e.g. blood, urine and 
tissue. However, since the latter substrate cannot be obtained non-invasively, 
tissue is less suitable to serve as a screening tool. In contrast to urine and blood, 
which can be gained in a more non-invasive manner and could therefore serve 
as a promising substrate for biomarker measurement. Hypothetically, due to 
the anatomical localisation of the prostate in relation to the urethra, urine could 
serve as an easy to obtain substrate to represent biochemical processes within 
the prostate. Therefore, there might be a potential role for urinary biomarkers in 
PCa management. By performing pressure to the prostate, as is done with a DRE, 
biomarker expression in the first-catch urine is increased.26, 27   
17
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Table 1. Clinically useful biom
arkers and com
m
ercially available tests for prostate cancer
H
igh-grade	prostate	cancer	is	defined	as	G
leason	score	≥7.	A
S:	acti
ve	surveillance;	CE	IV
D
:	conform
ité	Européenne	in	vitro	diagnosti
cs;	CLIA
:	
clinical	laboratory	im
provem
ent	am
endm
ents;	CRPC:	castrati
on-resistant	prostate	cancer;	CTC:	circulati
ng	tum
or	cells;	FD
A
:	food	and	drug	
adm
inistrati
on;	ISO
:	internati
onal	organizati
on	for	standardizati
on;	O
S:	overall	survival;	PH
I:	prostate	health	index;	RU
O
:	research	use	only.
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Prostate Cancer Antigen 3 
Identification	of	the	prostate	cancer	antigen	3	gene
Prostate Cancer Antigen 3 (PCA3) was first described as the Differential Display 
clone 3 (DD3) gene in 1999 as a prostate specific non-coding messenger RNA 
(mRNA) found to be highly overexpressed in PCa tissue compared to non-neoplastic 
prostate tissue. PCA3 overexpression was seen in 95% of prostate cancers, with a 
median 66-fold upregulation and no expression in non-prostate tissue.28 
Two studies showed an improvement of diagnostic accuracy and specificity of 
the reverse transcription polymerase chain reaction (RT-PCR) PCA3 assay over 
PSA. The first study, including 108 men undergoing prostate biopsies, showed 
an AUC of 0.72 (95% confidence interval (CI) 0.58-0.85) for PCa outcome and a 
sensitivity and specificity of 67% and 83%, respectively.26 In another multicenter 
study involving 583 men, the urinary PCA3 assay had an AUC of 0.66 (95% CI 
0.61-0.71) compared to 0.57 (95% CI 0.52-0.63) for PSA, with a PCA3 sensitivity 
and specificity of 65% and 66%, respectively. In comparison, PSA (between 3-15 
ng/mL) had a sensitivity of 65% and a specificity of 47%.29
Translation	to	a	transcription-mediated	amplification	assay
In 2006 a transcription-mediated amplification assay was designed to translate the 
RT-PCR based urinary PCA3 assay into the commercially available PCA3 Progensa® 
test (Gen-Probe, Inc.). In this test whole urine is used, in which a quantitative 
PCA3 score is calculated as a ratio between PCA3 and PSA mRNA ([PCA3 mRNA/
PSA mRNA] x 1000).30 PSA mRNA concentrations are used in this calculation 
to normalise for the amount of prostate-specific mRNA in the molecular test 
samples, since KLK3, the gene that encodes for PSA, is not upregulated in PCa.30 
The Progensa PCA3 assay can be applied on first-catch urine obtained after 
performing a DRE (three strokes per lobe) that shed prostate (cancer) cells into 
the urethra. This method of urine collection provides higher informative rates 
compared to samples obtained without performing a DRE.31
Clinical	implication;	diagnostic	utility	in	the	prostate	biopsy	setting	
The diagnostic performance of the PCA3 test has been extensively studied and 
gained USA Food and Drug Administration (FDA) approval in 2012 as an aid 
tool for decision making in the repeat biopsy setting, with a cut-off value of 
25. The likelihood of harbouring PCa increases as the PCA3 score is higher.32, 
33 Consequently, the most accurate and optimal cut-off value is still subject 
to discussion and is mostly based on a compromise between sensitivity and 
specificity. Various studies demonstrated an optimal balance between sensitivity 
and specificity using a PCA3 score of 35,32, 34-36 whereas others suggest the cut-off 
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at 25.37, 38 The major drawback in these studies is the fact that prostate biopsy 
outcome is used as a golden standard, whereas the number of men who actually 
have PCa might be higher.
To aid in the identification of men at risk for PCa and improve diagnostic accuracy, 
various PCa risk tables and nomograms have been developed. In a study described 
by Hansen et al., PCA3 was added to established clinical risk factors, to develop 
a nomogram for decision making in the initial prostate biopsy setting.39 Adding 
PCA3 (with a cut-off value of 21) to this nomogram showed highest diagnostic 
accuracy with an AUC of 0.81; an increment of 7.1% in contrast to the base 
model consisting of age, PSA, prostate volume and DRE findings. Four other large 
clinical studies showed that PCA3 fulfils the criteria for a novel marker capable 
of increasing the predictive accuracy of multivariate biopsy models.40-43 Hence, 
adding PCA3 to the developed nomograms may aid in guiding biopsy decision. 
PCA3	as	a	prognostic	tool
Several studies assessed the role of PCA3 as a marker to monitor PCa 
aggressiveness (e.g. clinical/pathological stage, Gleason score, tumour volume, 
extra prostatic extension) at prostate biopsies.26, 32, 36 However, in these studies 
there was no significant correlation found. Moreover, various studies have 
assessed PCA3 scores in relation to pathological features by using prostatectomy 
specimen as an outcome. In 2008 Van Gils et al. described a study including 62 
men who underwent a radical prostatectomy and they assessed the PCA3 score 
in correlation with prognostic parameters.44 No significant correlation was found 
between the PCA3 score and any of the investigated parameters. These findings 
were confirmed by a second study in which the same patient cohort was used, 
and by a recent study from the same research group who assessed a different 
patient population.45, 46 On the contrary, Durand et al. described a study in which 
they assessed the correlation between the PCA3 score and radical prostatectomy 
(RP) outcome in 160 patients. They found a significant correlation between PCA3 
scores and tumour volume as well as positive resection margin risk on RP samples, 
considering a value of 35 as the most efficient value to predict tumour volumes 
>0.5 mL and positive resection margins on RP.47 Nakanishi et al. and Ploussard et al. 
also found a significant relationship between the PCA3 score and tumour volume 
as they evaluated 83 and 106 patients who underwent a RP, respectively.38, 48 In 
addition, in the study described by Nakanishi et al., higher PCA3 scores were also 
associated with a higher Gleason score. 
The largest study to date, published by Auprich et al. included 305 patients who 
underwent RP. In this study PCA3 was not found to be a significant predictor for 
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extra prostatic extension, seminal vesicle invasion or high grade disease at RP 
specimen (Gleason score ≥7) and PCA3 currently has no role in risk assessment 
during active surveillance protocols.37, 49 
In conclusion, several studies that have evaluated PCA3 as a potential prognostic 
marker showed controversial results. However, PCA3 seems most likely to be 
associated with tumour volumes and its role in the prediction of aggressive 
tumours seems limited. It is assumed that lower Gleason score tumours are 
characterised by larger glandular lumina compared to higher Gleason score 
cancers, where glands appear to be fused. In this way, tumour cells might be 
easier shed into the glandular system in lower Gleason score tumours, resulting 
in higher PCA3 scores. 
Transmembrane Protease, Serine 2 – ETS fusion 
By using a method named cancer outlier profile analysis (COPA), genes that are 
differentially expressed in different tumours can be identified. With this technique 
Tomlins et al. described in 2005 that gene members of the ETS family (v-ets 
erythroblastosis virus E26 oncogene; ERG and ETS variant gene 1; ETV1) were 
markedly overexpressed in 57% of PCa cases. Furthermore, they found fusion 
with the 5’ untranslated region of the androgen-regulated gene transmembrane 
protease, serine 2 (TMPRSS2) in over 90% of cases that overexpressed ERG or 
ETV1, suggesting that the fusion is most likely the cause of the overexpression.50 
The existence of this androgen regulated gene fusion between TMPRSS2 and ERG 
may fulfil an important role in PCa diagnostics and management. In 2006 it was 
demonstrated that TMPRSS2-ERG fusion transcripts could be detected in urine 
samples of patients with PCa.51
The TMPRSS2-ERG gene fusion is highly PCa specific and has been found in 
approximately 50% of the PSA-screened prostate adenocarcinomas in the 
Caucasian population and with lower incidence in Asian cohorts.52, 53 The urine 
based assay was studied in a pre-biopsy cohort consisting of 108 patients. The 
TMPRSS2-ERG fusion had a sensitivity of 37%, a specificity of 93% and a positive 
predictive value (PPV) of 94% in post-DRE urine samples for the presence of PCa 
upon biopsy.54 Given this high specificity, it suggests that this gene might potentially 
fulfil an important clinical role in determining whether PCa is present or absent. 
However, as most of the PCas have multiple tumour foci, TMPRSS2-ERG status is 
commonly heterogeneous between these foci within the same prostate.55 Tomlins 
et al. suggested that due to this heterogeneous nature of the disease, a binary 
rendering (positive/negative) of TMPRSS2-ERG expression in urine of men with 
PCa would not per definition reflect the extensiveness of the disease.55 Despite 
21
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TMPRSS2-ERG expression can be displayed as a continuous variable, using a 
certain cut-off, a balance between sensitivity and specificity could be gained, as is 
also the case with the PCA3 score. Another way to overcome the low sensitivity 
of TMPRSS2-ERG and reflect the heterogeneity of PCa, is to combine several 
biomarkers in a panel.
TMPRSS2-ERG	fusion	as	a	prognostic	tool	in	PCa	management
Several studies aimed to investigate whether the TMPRSS2-ERG fusion is associated 
with a more aggressive PCa phenotype and therefore could predict worse 
prognosis. The largest study so far, assessed the association between ERG protein 
overexpression in tissue in a cohort including 1,180 men treated with radical 
prostatectomy and found overexpression in 49%.53 This ERG overexpression was 
correlated with a higher tumour stage (p<0.01). On the contrary, no association 
was found between ERG overexpression and Gleason score (p=0.58), lethal 
PCa (metastases to distant organs, bones and PCa death) (p=0.99), biochemical 
recurrence after RP (p=0.96) or all-cause mortality (p=0.60).53 In a meta-analysis 
including 61 studies, men with TMPRSS2-ERG-positive cancers were somewhat 
more likely to have advanced stage tumours (≥T3 versus ≤T2). Fusion status was 
not associated with risk of Gleason 8-10 versus Gleason 2-6 (risk ratio (RR), 0.99; 
95% CI 0.86-1.13) or Gleason 7 versus Gleason 2-6 (RR, 1.05; 95% CI 0.99-1.12).53 
These results suggested that TMPRSS2-ERG is not a strong predictive marker of 
disease outcome among men treated with RP. Another study, not included in the 
meta-analysis, assessed the fusion transcript in urinary sediment of pre-biopsy 
patients. In 37% of the PCa patients TMPRSS2-ERG was detected in the urine. 
No correlation was found between the presence of TMPRSS2-ERG transcripts and 
Gleason score (p=0.511).54 
On the other hand, results from various previous studies suggested that the 
presence of the TMPRSS2-ERG fusion is associated with higher tumour stage and 
PCa specific death. In 2007 Demichelis et al. identified a statistically significant 
association between TMPRSS2-ERG fusion, higher Gleason scores (p=0.01) and 
PCa specific death (p<0.01) in a group of 111 men with low stage PCa (T1a-b Nx 
M0). However, in this cohort TMPRSS2-ERG fusion was detected in only 15% of 
the PCa patients, whereas other studies documented a positive TMPRSS2-ERG 
fusion rate of approximately 50%.56 Additionally, Leyten et al. described a 
significant higher TMPRSS2-ERG expression in urine samples from patients with 
a Gleason score ≥7 (p<0.01) and clinical tumour stage T3-4 (p=0.003).46 These 
results suggest that TMPRSS2-ERG fusion presence might be associated with 
tumour stage, however, correlation with Gleason score and PCa specific death 
showed contradictory results.
22
PCA3 + TMPRSS2-ERG combined biomarker panel
Since PCa is a heterogeneous disease with each tumour displaying its own 
characteristics, a panel of biomarkers would be more suitable to improve the 
diagnosis of PCa. Several studies have assessed the PCA3 score in combination 
with TMPRSS2-ERG expression to predict prostate biopsy outcome. In 2007 
Hessels et al. described a prospective study in which post-DRE urine samples 
from 108 pre-biopsy patients were collected for biomarker analysis. In this cohort, 
72% had PCa upon biopsy. When a cut-off value of 58 was used for PCA3, 48 
(62%) PCa were detected. Combining both PCA3 and TMPRSS2-ERG the number 
of PCas diagnosed, increased with 11% to 57 patients (73%).54 Laxman et al. 
described a multiplexed model with four putative biomarkers, including PCA3 and 
TMPRSS2-ERG. This combination panel showed a sensitivity and specificity for 
PCa detection of 65.9% and 76%, respectively.57 Another study evaluated a model 
including PCA3, TMPRSS2-ERG, Annexin A3 and Sarcosine for PCa diagnosis. The 
diagnostic accuracy of this model outperformed any of the single biomarkers 
(AUC 0.856 versus PCA3: 0.739, TMPRSS2-ERG: 0.732, Annexin A3: 0.728 and 
Sarcosine: 0.665).58 
Furthermore, a study by Leyten et al. assessed the combination of urinary PCA3 
and TMPRSS2-ERG to improve diagnostic accuracy in a series of 443 men of which 
44% had PCa upon biopsy. Predictive values were calculated in addition to the 
ERSPC risk calculator. Using these parameters, the ERSPC risk calculator alone had 
an AUC of 0.799 to predict PCa. This increased to 0.833 when PCA3 was added 
and to 0.842 when both PCA3 and TMPRSS2-ERG were added.46 For the prediction 
of clinically significant PCa (clinical stage ≥T2, Gleason score ≥7, PSA density 
>0.15, and >33% positive cores) PCA3 alone, with a cut-off value of 25, had a 
sensitivity and specificity of 81% and 51%, respectively. When combined with 
TMPRSS2-ERG sensitivity increased to 88% without comprising the specificity of 
PCA3. Noteworthy however, in this cohort the diagnostic accuracy of significant 
PCa almost equals that of any PCa, as 90% had significant PCa.46 Tomlins et al. 
also incorporated both the PCa specific urine markers in a multivariate (PCPT) 
risk calculator with PSA to improve the predictive accuracy of PCa and high-grade 
PCa upon biopsy. The urine PCA3 and TMPRSS2-ERG biomarker panel, combined 
with the PCPT risk calculator demonstrated an AUC of 0.779 for the presence of 
high-grade PCa (Gleason > 6) upon biopsy. This test is now commercially available 
as the Mi-Prostate Score (MiPS).59 
MicroRNA
MicroRNAs (miRNAs) are small, non-coding single-stranded RNAs, with a length 
of approximately 19-23 nucleotides, that play a role in cell gene expression. 
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miRNAs have specific functions in various biological processes through their 
interaction with cellular mRNA, such as apoptosis and cell cycle control. 
miRNAs can be detected in serum, plasma, saliva and urine, and have been 
shown to be associated with various pathological conditions, including cancer.60 
Their presence in various body fluids makes it a potential approach to obtain 
information about cancerous conditions in a non-invasive manner. In PCa, several 
miRNAs appear to have important mechanistic roles with respect to apoptosis 
avoidance, proliferation, epithelial-to-mesenchymal transition and development 
of androgen independence.61 The small size of miRNAs is suggested to protect 
them from RNAse as they are also secreted within protective exosomes. A 
recently published study described miRNA quantification in urine samples. In 
118 PCa patients and 17 healthy controls it was feasible to successfully quantify 
five selected miRNAs, of which miR-107 and miR-574-3p were found to have 
significantly higher concentrations in the urine of men with cancer, compared 
with the controls.61 They even appeared more accurate than PCA3 normalised 
to urinary PSA to identify the presence of PCa.61 Since this is the only study on 
PCa miRNA detection in urine to date, most studies assessed miRNA in serum 
and plasma. Across these studies, two miRNAs (miR-141 and miR-375) were 
suggested as diagnostic and prognostic markers. Elevated serum level of miR-141 
has been correlated with metastatic PCa compared to local PCa, and together 
with miR-375 it was also associated with higher Gleason score and positive lymph 
node status.62 These findings suggest that miRNAs may assist in the diagnosis and 
prognosis of PCa. However, detection and validation of miRNAs as a urine and 
serum biomarker is still at an early stage of research, and the majority of studies 
to date used only small patient cohorts (<200 men).62 Therefore, these promising 
results need further validation in larger prospective patient studies conducted 
according to standardised, robust methodology and standards for sampling the 
biological material and profiling the miRNAs.63 
Exosomes
Recent findings revealed that small tissue-derived vesicles (30-100 nm in diameter), 
called exosomes, are secreted by various cell types, including tumour cells. They 
contain a wide variety of proteins and RNAs that represent their tissue origin.64 
These exosomes can be found in various body fluids (e.g. blood, urine, semen). The 
presence of exosomes in urine and the fact of carrying genetic information, makes 
it a promising non-invasive substrate for biomarkers. Moreover, exosomes lack 
essentially all of the ribosomal RNA and thus contain mainly mRNAs and miRNAs.65 
As exosomes are the internal vesicles of multivesicular bodies it is suggested that 
mRNA therefore is better preserved within the exosomes compared with whole 
cells isolated from urine.66 
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Only a few studies have assessed the role of exosomes as a PCa biomarker 
substrate. In 2009 Nilsson et al. for the first time described the presence of PCA3 
and TMPRSS2-ERG in exosomes isolated from the urine of PCa patients.65 Urine 
samples were collected for biomarker analysis before and after DRE from nine 
PCa patients (four untreated patients, two treated with androgen-deprivation 
therapy (ADT), three with verified bone metastases). In all four untreated 
patients, positive PSA and PCA3 mRNA levels could be detected in the exosomes 
after DRE, and TMPRSS2-ERG mRNA was detected in 2/4 patients. Neither of the 
ADT patients or the patients with verified bone metastases had detectable PSA, 
PCA3 or TMPRSS2-ERG mRNA levels.65 The latter can be explained by the finding 
of Mitchell et al. who described a 2-fold decrease in urinary exosome content 
following ADT.67 In a larger study by Donovan et al. exosomal PCA3 and ERG 
were measured in non-DRE urine from 195 men scheduled to undergo prostate 
biopsy. A dichotomous score (the sum of PCA3 and ERG mRNA levels; EXO106) 
was computed and performance was compared with clinical parameters (PSA, 
age, race or family history). Results for the EXO106 score showed a negative and 
positive predictive value of 97.5% and 34.5% for high-grade disease and addition 
of the EXO106 score to the clinical parameters significantly improved the AUC.68
The results of detecting PCa specific biomarkers within exosomes are promising 
and this substrate may offer potential in future PCa management. However, 
more studies are needed to gain additional knowledge about the clinical 
value of exosomes. Furthermore, current methods for exosome isolation are 
comprehensive and time consuming. Future studies might gain methodological 
improvement in isolating exosomes.
NOVEL BLOOD-BASED PROSTATE CANCER BIOMARKERS
With the current development and upcoming treatment options in advanced PCa, 
together with the fact that PSA levels may not accurately reflect disease status, 
the need for finding reliable indicators of disease status and predictors of therapy 
outcome is growing. A blood sample will be the most interesting substrate to 
detect these biomarkers in disseminated PCa patients.
Circulating tumor cells
The presence of circulating tumor cells (CTCs) in the peripheral blood and their 
role in distant metastases development has already been described in 1869, in 
a man with metastatic disease. More recently, a technology to enumerate CTCs 
from the blood received regulatory clearance from the FDA in 2004 for metastatic 
breast cancer patients. Subsequently, the clinical utility of the CellSearch System 
(Veridex LLC) has been further evaluated in patients with metastatic PCa since 
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2007. De Bono et al. described a correlation between the number of CTCs in 
7.5 mL blood of castration-resistant prostate cancer (CRPC) patients and overall 
survival by using this CellSearch System.69 They evaluated 231 patients with 
progressing CRPC and showed that the CTC number, defined as favourable (<5 
CTCs) or unfavourable (≥5 CTCs), at different time points after treatment was 
the strongest independent predictor of overall survival.69 The CTC number also 
showed to be more predictive than post therapy changes in PSA. These results 
were confirmed in other studies by Olmos et al. and Scher et al.70, 71 Another study 
however, found that baseline CTCs, used as a continuous variable, to be predictive 
of survival, without a threshold effect.72 
To investigate treatment response, Danila et al. and Reid et al. incorporated CTC 
analysis within two phase II studies to assess abiraterone treatment in CRPC 
patients. In these studies, respectively, 34% and 41% showed conversion from 
unfavourable CTC count (≥5 CTCs) to favourable CTC count (<5 CTCs).73, 74 These 
findings might emphasise the CTC enumeration as a potential surrogate biomarker 
of therapy response and survival. In a phase III trial of docetaxel with or without 
atrasentan for CRPC patients, baseline CTC count (<5 CTCs or ≥5 CTCs) proved 
to be significantly associated with overall survival.75 Nevertheless, future studies 
should provide more evidence at this point before CTCs can be implemented as a 
tool to redirect and optimize patient therapy.
A recent development in CTCs molecular profiling is the detection of 
androgen-receptor splice variant 7 messenger RNA (AR-V7) in CTCs of CRPC 
patients as a potential predictive biomarker. Antonarakis et al. were able to 
detect AR-V7 in CTCs in 39% and 19% of patients treated with enzalutamide and 
abiraterone, respectively. AR-V7 positive patients had lower PSA response rates, 
shorter PSA progression-free survival, clinical or radiographic progression-free 
survival and overall survival compared to AR-V7 negative patients.76 The detection 
of AR-V7 in CTCs may therefore be associated with resistance to enzalutamide and 
abiraterone, however, clinical validation in large prospective studies is required. 
Molecular profiling of peripheral blood mononuclear cells
Through molecular profiling of CTCs, information about tumour characteristics can 
be gained and potentially contribute to a treatment decision. In 1994 Katz et al. 
already described the ability to detect PSA mRNA from the blood of PCa patients.77 
In the metastatic PCa patients 77.8% was positive for PSA mRNA and in the 
patients with clinically localised PCa, 38.5%. In addition, none of the 40 specimen 
from women or men without PCa was positive.77 Furthermore, in 2008 Väänänen 
et al. examined the role of PCA3 in peripheral blood from 67 PCa patients, of 
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which nine had metastatic PCa. Two of the nine metastatic PCa patients had levels 
of PCA3 mRNA above the limit of quantification and four of the nine had positive 
levels of PSA mRNA.78 A more recent study by Danila et al. assessed the role of 
TMPRSS2-ERG in CTCs of CRPC patients commencing abiraterone treatment. They 
found TMPRSS2-ERG expression in blood samples of 15 of 41 CRPC patients (37%) 
prior to treatment initiation. However, TMPRSS2-ERG fusion status by itself had 
a limited role as a predictive biomarker of sensitivity to abiraterone treatment in 
this cohort with post-chemotherapy treated CRPC patients.79 
Furthermore, several other genes and gene panels have been investigated in the 
blood of PCa patients. In a study by Liong et al. blood mRNA from North American 
and Malaysian PCa patients and controls was assessed to identify biomarkers for 
aggressive PCa. By microarray data mining and PCR data evaluation of the blood 
samples they were able to identify a panel consisting of seven biomarkers.80 This 
panel improved PSA accuracy for the prediction of aggressive cancers. However, 
results are preliminary and need validation in a multicenter clinical study 
containing a more extended population.
Another recent study by Danila et al. described an analytic and clinical validation of 
a prostate cancer-enhanced mRNA detection assay in whole blood as a prognostic 
biomarker panel for survival. In this study they identified a 5-gene panel, consisting 
of KLK3, KLK2, HOXB13, GRHL2 and FOXA1, and measured these markers in blood 
samples from 97 metastatic CRPC patients with progressive disease.81 The results 
showed that expression of at least two of the five genes was a strong prognostic 
factor for survival, comparable with the CellSearch system. Combining both the 
gene panel and the CellSearch resulted in an enhanced power to discriminate 
between low- and high-risk patients relative to CellSearch alone.   
Although only small patient groups were used in the few studies that evaluated 
the presence of PCa specific biomarkers in peripheral blood samples, results are 
encouraging.
NOVEL TISSUE-BASED PROSTATE CANCER BIOMARKERS
Tissue markers can be of value once prostate biopsies have been taken or a 
prostatectomy specimen is available. Examples of markers which have been 
assessed for their prognostic role in PCa are Ki-67, PTEN, E-Cadherin and EZH2.82-85 
Over the years also various other biomarkers have been identified in prostate 
tissue and these discoveries have led to the development of multiple commercially 
available genetic tests to predict PCa presence and/or PCa aggressiveness. Recent 
studies described the prognostic value of a predefined cell cycle progression 
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score using the expression of 31 genes in prostate (cancer) tissue. This score was 
validated to have significant prognostic accuracy (pre- and post-prostatectomy) 
and was subsequently developed into the commercially available Prolaris 
(Myriad Genetics, Inc.) test.86, 87 Another currently available test to identify which 
low-risk patients can be managed by active surveillance and which patients need 
immediate treatment, is the Oncotype DX (Genomic Health, Inc.) PCa assay. This 
assay is based on a score derived from the expression of 17 genes that can predict 
the aggressiveness of PCa.88
By detecting an epigenetic field or “halo” associated with the cancerization process 
at the DNA level in cells adjacent to cancer foci, the commercial ConfirmMDx 
(MDxHealth, Inc.) test can aid in the identification of high-risk men who may 
need to undergo repeat biopsies. Prior to the development of this test, Trock et 
al. evaluated the performance of DNA methylation biomarkers (APC and GSTP1) 
in 86 men with an initial histologically negative prostate biopsy session and the 
commercial test (APC, GSTP1 and RASSF1) was validated in cancer negative 
prostate biopsy core tissue samples of 350 subjects resulting in a NPV of 88% with 
an odds ratio of 2.69 as most significant independent predictor of biopsy outcome 
after 24 months.89, 90 
A fourth tissue-based commercially available test is Decipher (GenomeDX 
Biosciences), which is developed and validated as a specific predictor of 
biochemical recurrence and PCa specific mortality in men that underwent a 
radical prostatectomy. This test is based on a 22 gene panel and may contribute 
to decision making for adjuvant treatment after prostatectomy.91 
Since current evidence is fairly marginal, these tests and markers need further 
assessment. Another challenging step in this evolution will be to adapt these 
markers for testing and use in CRPC patients.  
CONCLUSIONS
Although various novel markers have been implemented in daily practice, PSA 
currently remains the most widely used biomarker in both PCa diagnostics and 
follow-up. However, its lack of specificity has caused an increase in the number 
of diagnostic prostate biopsies worldwide and subsequently an increase in 
insignificant PCa incidence, resulting in potential overtreatment, a psychological 
burden to the patient and increasing health care costs. This major drawback of 
PSA testing and the tremendous progress that has been made in the field of 
molecular profiling the last decades, has led to the discovery of various novel, 
promising biomarkers.
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However, many published results on novel PCa biomarkers appear not 
reproducible in subsequent studies and thus will never attain the FDA approved 
status. Where a double-blind randomized placebo controlled trial is the gold 
standard for therapeutic studies, biomarker studies are not regulated by clear 
guidelines. These studies often suffer poor study design, lack methodological 
quality and standardized assays, and information on key elements of design and 
analysis are often not reported. To improve the quality of diagnostic studies, the 
STARD (STAndards for Reporting of Diagnostic accuracy) statement was developed 
to ensure that all relevant information is present. In addition, the REMARK 
guidelines (Reporting Recommendations for Tumor Marker Prognostic Studies) 
were published in 2005 for transparent and complete reporting of studies, so that 
poor studies can be better identified. These initiatives are important steps forward 
in improving the quality of tumour marker studies, although further improvement 
of future studies is warranted. 
Given the anatomical localisation of the prostate in relation to the urethra, and 
the fact that prostate cells can be released into the urethra by performing a DRE, 
urine can serve as an ideal, non-invasive, easy to obtain substrate to acquire 
information about biochemical processes within the prostate. 
Although genetic sequencing resulted in the identification of multiple promising 
markers, to date only few of these markers have shown to obtain characteristics 
to serve as a useful non-invasive urinary marker. In PCa diagnostics, two urinary 
biomarkers and two blood-based biomarkers gained extraordinary interest as PCa 
specific markers, namely PCA3, TMPRSS2-ERG, the prostate health index (phi) and 
the 4K score. These markers showed higher specificity and diagnostic accuracy for 
PCa outcome compared to PSA, which, in clinical use, may lead to the reduction 
of unnecessary biopsies.   
Concerning the heterogeneity of the disease, the future prospect will have to be 
focused on the combination of biomarkers to improve the prediction of high-grade 
PCa. Moreover, to establish an individualized and personalized approach for 
diagnosis and treatment of PCa, biomarker panels should be incorporated with 
relevant clinical parameters and other valuable modalities (i.e. imaging) into a 
personal risk stratification. Furthermore, finding a marker that can function as 
a non-invasive aid tool in the management of CRPC treatment is important. 
The detection of CTCs within the blood seems a promising method to predict 
treatment response and survival benefit. However, studies aiming to detect PCa 
specific biomarkers within peripheral blood mononuclear cells are also ongoing 
and more results in this field are to be expected.
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ABSTRACT
Purpose
Urinary biomarker tests for diagnosing prostate cancer have gained considerable 
interest. Urine is a complex mixture that can be subfractionated. We evaluated 
two urinary fractions that contain nucleic acids, i.e. cell pellets and exosomes. 
The influence of a digital rectal examination before urine collection was also 
studied and the prostate cancer specific biomarkers PCA3 and TMPRSS2-ERG 
were assayed.
Materials and Methods
Urine samples were prospectively obtained before and after digital rectal 
examination from 30 men scheduled for prostate biopsy. Cell pellet and exosomes 
were isolated and used for biomarker analysis. Analytical and diagnostic 
performance was tested using the Student t-test and ROC curves. 
Results
Unlike the exosome fraction, urinary sediment gene expression analysis was 
compromised by amorphous precipitation in 10% of all specimens. Digital 
rectal examination resulted in increased mRNA levels in each fraction. This was 
particularly relevant for the exosomal fraction since after digital rectal examination 
the number of samples decreased in which cancer specific markers were
below the analytical detection limit. Biomarker diagnostic performance was 
comparable to that in large clinical studies. In exosomes the biomarkers had to 
be normalized for prostate specific antigen mRNA while cell pellet absolute PCA3 
levels had diagnostic value.
Conclusions
Exosomes have characteristics that enable them to serve as a stable substrate 
for biomarker analysis. Thus, digital rectal examination enhances the analytical 
performance of biomarker analysis in exosomes and cell pellets. The diagnostic 
performance of biomarkers in exosomes differs from that of cell pellets. Clinical 
usefulness must be prospectively assessed in larger clinical cohorts.
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INTRODUCTION
Prostate cancer (PCa) is the most common malignancy in males in developed 
countries and the third leading cause of cancer related death in this population.1 
The gold standard of PCa diagnosis is based on histopathological examination of 
prostate biopsies. The indication for prostate biopsies primarily relies on serum 
PSA and/or suspicious DRE. The introduction of serum PSA testing led to a 
considerable increase in the number of prostate biopsies, which in turn led to an 
increase in the PCa incidence. Although serum PSA has low specificity for detecting 
PCa, it is currently the only biomarker used in clinical practice for PCa diagnosis. 
However, it does not differentiate between indolent and clinically significant PCa. 
Therefore, better diagnostic and monitoring tools are urgently needed.
A new biomarker should ideally meet certain criteria. It should be a noninvasive 
test that is produced by tumor tissue only and has the ability to detect PCa at an 
early stage. Thus, it should differentiate aggressive from indolent tumors with 
high specificity and sensitivity. To date several urinary biomarkers for PCa have 
been investigated. In 1999 Bussemakers et al. noted that the prostate specific 
noncoding RNA DD3, better known as PCA3, is highly over expressed in prostate 
tumor tissue.2 Further research recently led to Food and Drug Administration 
approval of the commercially available PCA3 urine test, calculated as PCA3 mRNA/
PSA mRNA x 1,000, as a decision making aid for repeat biopsy. Another biomarker 
strongly associated with malignant prostate epithelial cells is the TMPRSS2-ERG 
gene fusion transcript.3 This androgen regulated gene fusion is found in almost 
50% of patients with PCa and it is absent in non PCa specimens.4 Each biomarker 
can be measured noninvasively in urinary samples.
Urinary samples can be a noninvasive substrate for biomarker analysis using 
various components of urine. In most previous studies biomarkers were analyzed 
in whole urine or urinary sediments. Recent findings revealed that small tissue 
derived vesicles called exosomes are a component of urine and contain a wide 
variety of proteins and RNAs that represent the tissue of origin.5, 6 However, few 
groups have examined the role of these exosomes as a novel substrate for PCa 
biomarkers.7-9
Biomarker expression in urinary samples is expected to be higher after performing 
DRE, considering that prostate manipulation mobilizes cancer cells, if present, 
via the prostatic ductal system into the urethra. Subsequently, first catch urine 
contains the highest concentration of prostate secretions, including cells. This 
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hypothesis was investigated in previous series.10, 11 In a pilot study Nilsson et al 
noted that mild prostate manipulation increased exosomal secretion into the first 
catch urinary fraction.9 
We further investigated urinary exosomes as a substrate for PCa biomarkers by 
assaying PCA3 and TMPRSS2-ERG in cell pellets and exosomes before and after 
DRE. PSA mRNA levels were determined for normalization as a prostate reference 
gene. The diagnostic value of PCA3 in exosomes and cell pellets for biopsy outcome 
prediction was also evaluated.
MATERIALS AND METHODS
Data collection
Urinary samples were prospectively taken from 30 patients at the outpatient clinic 
of two university hospitals in The Netherlands in an almost equal ratio. Approval 
was obtained from the institutional review boards in accordance with all medical 
ethical requirements. Patients were scheduled for prostate biopsies based on 
PSA (≥ 3 ng/ml) and/or abnormal DRE. After obtaining written informed consent 
first catch urine collection was done without DRE. Standardized DRE was then 
performed with firm pressure to the prostate from base to apex and from the 
lateral to the medial side.12 Directly after DRE a second first catch urine sample 
was collected and transrectal ultrasound guided prostate biopsies were obtained 
according to the local protocol (8 to 16 cores). Pathology results and all other 
clinical data were collected prospectively.
Cell pellet and exosome isolation
Coded 50 ml transfer tubes containing 4 ml 0.5 M ethylenediaminetetraacetic 
acid were used for urine collection. After collection samples were immediately 
cooled and processed within 48 hours to maintain optimal sample quality. 
Analysis was done at a central laboratory. Cell pellet and exosome isolation were 
performed according to a validated procedure.13 Cell pellets were separated from 
supernatant at 1,800 x gravity for 10 minutes at 4°C, washed twice with ice-cold 
buffered sodium chloride solution, snap frozen in liquid nitrogen and stored at 
-70°C. Cellular debris was removed from supernatant containing exosomes by 
centrifuging at 3,200 x gravity for 90 minutes at 4°C, followed by filtration using 
a 0.8 mm filter. The concentrate containing exosomes was obtained by filtration 
through a 100 kDa filter using a Vivaspin® centrifuge. The acquired exosome 
content was washed twice with ice-cold buffered sodium chloride solution, snap 
frozen in liquid nitrogen and stored at -70C.
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Real-time PCR RNA extraction and gene expression analysis
RNA was extracted from exosomes and cell pellets using a modified TriPure® 
Reagent protocol (catalogue No.11667165001). GlycoBlue™ (15 mg/ml, catalogue 
No. AM 9515) served as the carrier to co-precipitate RNA. RNA samples were 
treated with DNase for 10 minutes before the amplification protocol using 
DNase I enzyme (catalogue No. 18068-015, Invitrogen™). Total RNA was used to 
generate amplified sense strand cDNA using the Whole Transcriptome Analysis Kit 
(catalogue No. 4411974, Ambion®) according to the manufacturer protocol. PSA, 
PCA3 and TMPRSS2-ERG expression levels were analyzed by quantitative realtime 
PCR, normalized to the amount of urine used and expressed in copies per ml. 
Two µl of each cDNA sample were amplified in a 20 µl PCR reaction containing 10 
µmol of each primer, 2 µmol hydrolysis probe and 1x Probes Master mix (Roche, 
Indianapolis, Indiana). 
Control samples served as the referent. Amplification conditions were 95°C for 10 
minutes followed by 50 cycles at 95°C for 10 seconds and 60°C for 30 seconds with 
cooling at 40°C for 55 seconds using a LightCycler® LC480. LightCycler 480 SW 1.5 
software was used to determine crossing point values. Calibration curves with a 
wide linear dynamic range (10 to 1,000,000 copies) were generated using plasmid 
serial dilutions. We converted sample crossing point values to concentrations by 
extrapolation in the generated calibration curve. 
The cutoff value for an adequate amount of prostate content was set at 1,000 
copies of PSA mRNA.14 Copy numbers below this cutoff were assumed to contain 
an insufficient amount of prostate specific transcripts and be less accurate and 
reliable. Therefore, they were excluded from further diagnostic analysis. To test 
the analytical performance no exclusion was done based on the mentioned 
criteria since the amount of prostate specific transcripts measured could possibly 
have been influenced by a DRE.
Electron microscopy
Exosome isolation for electron microscopy imaging was done in one urine sample 
according to the mentioned methods. For immunoelectron microscopy exosome 
identification we used the protocol described by Lässer et al.15 Figure 1 shows a 
urinary exosome.
Statistical analysis
Data were analyzed using SPSS®, version 18.0.2. To test for differences in 
biomarker expression before versus after DRE we used the paired sample t-test 
after log transformation of data. ROC curve analysis and the AUC were applied to 
calculate diagnostic accuracy.
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Figure 1.
Immunoelectron microscopy shows 
an exosome isolated from urine by 
ultrafiltration. Black dots attached to 
exosome indicates exosomal surface 
marker CD63. Scale bar indicates 
100 nm.
RESULTS
Patient characteristics
A total of 30 patients were included in the study, from whom a total of 60 urinary 
samples were collected. For analysis we used a urinary sample obtained before 
and after DRE from each patient. All men subsequently underwent transrectal 
ultrasound guided prostate biopsies. PCa was found in the biopsy specimen in 14 
patients (47%). Table 1 lists patient characteristics. 
Table 1. Patient	characteristics
The amount of urine collected before DRE was similar to the amount collected 
after DRE (mean 36.8 and 39.2 ml, respectively, p = 0.255). In 3 samples (10%) 
before DRE and 3 (10%) after DRE no RNA was extracted from the cell pellet due 
to precipitation of impurities (crystals). Three samples (5%) did not fulfill the 
predetermined cutoff values for a sufficient amount of prostate specific transcripts, 
including 2 samples before and 1 after DRE. Another sample was lost in the RNA 
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extraction process. For urinary exosomes no precipitation occurred. However, 9 
samples (30%) before DRE and 6 (20%) after DRE did not fulfill the predetermined 
cutoff values for a sufficient amount of prostate specific transcripts. Therefore, 
for PCA3 mRNA diagnostic evaluation 25 post-DRE cell pellet samples and 24 
post-DRE exosome samples remained. Table 2 lists the number of samples with 
mRNA levels below the limit of detection (BDL) and nonassessable samples. BDL 
was defined as PSA less than 1,000 copies per ml and PCA3 less than 10 copies 
per ml. 
Table 2.	Nonassessable	and	BDL	samples	of	60	cell	pellet	and	exosome	samples
DRE:	digital	rectal	examination;	BDL:	below	the	limit	of	detection
*No	exosomes	were	nonassessable
RNA analysis
In total RNA from urinary sediments (cell pellets) we noted prominent 18S and 
28S peaks, representing rRNA. However, analysis of exosomal RNA showed a 
small, pronounced RNA peak between 25 and 200 nucleotides, and little or no 
ribosomal RNA. After treating the exosomal fraction with ribonuclease and DNase 
the extra-exosomal RNA and DNA were removed, resulting in exosome specific 
transcript preparations. 
Digital rectal examination and biomarker levels
Figure 2 shows the influence of DRE on biomarker expression levels in cell pellets 
and exosomes isolated from urinary samples. In the cell pellet fraction after 
DRE an increase in PSA mRNA was noted in 24 of 30 samples (80%), 22 of 30 
(73.3%) showed an increase in PCA3 mRNA and 5 of 6 (83.3%) were positive for 
TMPRSS2-ERG. In exosomal isolation samples an increase in PSA mRNA after DRE 
was observed in 22 of 30 (73.3%), 23 of 30 (76.7%) showed an increase in PCA3 
and 4 of 4 (100%) were positive for TMPRSS2-ERG. Mean biomarker levels were 
significantly higher in cell pellets and exosomes after DRE (Table 3).
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Figure 2. PSA mRNA in cell pellet (A) and exosomes (B), PCA3 mRNA in cell pellet (C) and 
exosomes (D), and TMPRSS2-ERG mRNA in cell pellet (E) and exosomes (F) before and 
after DRE.
Table 3.	Differences	in	biomarker	expression	in	cell	pellets	and	exosomes	before	and	after	
DRE	after	log	transformation	of	number	of	copies	mRNA/ml
DRE:	digital	rectal	examination;	SD:	standard	deviation
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Biomarker diagnostic performance
To assess the diagnostic performance of PCA3 we calculated ROC curves for biopsy 
outcome prediction (histologically confirmed PCa). As a continuous variable, PCA3 
mRNA copies showed an AUC of 0.67 (95% CI 0.45-0.89) in cell pellet samples 
before DRE and 0.81 (95% CI 0.64-0.98) after DRE. No reliable AUC could be 
calculated on exosome samples before DRE since in most samples mRNA levels 
were below the detection limit and, thus, were excluded from this analysis (table 
2). However, after DRE when more samples could be included in analysis, the AUC 
of absolute PCA3 mRNA was 0.52 (95% CI 0.28-0.76). When the quantitative PCA3 
mRNA level was normalized to PSA mRNA (PCA3 mRNA/PSA mRNA x 1,000), the 
AUC increased to 0.64 (95% CI 0.41-0.88) for exosomes. For cell pellets the AUC 
changed to 0.67 (95% CI 0.46-0.89) in samples obtained after DRE (Figure 3).
Figure 3. PCA3 expression in cell pellets (A) and exosomes (B) by positive biopsy outcome 
(PCa +) after DRE compared to negative biopsy outcome (PCa -). Horizontal lines represent 
mean. ROC curves after DRE for PCA3 mRNA in cell pellets without normalization for PSA 
mRNA and after normalization (AUC 0.81 and 0.67) (C), and for exosomes (AUC 0.52 and 
0.64, respectively) (D).
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DISCUSSION
Although progress has been made, validating new biomarkers in serum and 
urine remains a challenge. Our data show that first catch urine after DRE results 
in a clear increase in biomarker levels and, therefore, could contribute in PCa 
diagnosis. This increase was observed in cell pellets and exosomes.
Exosomes were first identified in human urine in 2004 and recent findings revealed 
that these small, tissue derived vesicles contain various RNAs, representing their 
tissue origin.5, 6, 16 Exosomes are the internal vesicles of multivesicular bodies, 
suggesting that exosomal RNA would be protected and better preserved than RNA 
in whole cells. This difference between RNA from exosomes and RNA derived from 
cells in urine was previously described.13 It corresponds with our results showing 
that microvesicles can resist ribonuclease and DNase digestion, and still protect 
the nucleic acids inside. In addition to this finding, the main difference between 
cell pellets and exosomes is that each exosome sample was assessable for RNA 
extraction, i.e. none of the exosome samples contained (in)organic precipitate 
while 3 cell pellet samples (10%) could not be assessed due to precipitation. No 
biomarker analysis can be performed in samples that contain precipitation and 
the clinical consequence of this would be resampling. The cell pellet informative 
rate in this study is in accordance with that in some earlier studies of PCA3 mRNA, 
emphasizing the more stable nature of exosomes over cell pellets.14, 17 
On the other hand, lower mRNA levels were measured in exosomes and a 
significant number of samples before DRE showed mRNA expression that was BLD, 
including 17 samples in exosomes versus 7 samples in cell pellets for PCA3 (Table 
2). However, this improved significantly after DRE, that is 5 samples in exosomes 
versus 2 samples in cell pellets. This supports the value of DRE for determining 
biomarkers in urine. Nevertheless, 16% to 20% of exosome samples did not 
achieve the analytical detection limit. In clinical practice these samples would be 
interpreted as a negative test. Therefore, low analytical sensitivity can lead to 
false-negative test results. This is a detriment of exosomes and makes them not 
yet suitable as a biomarker source for PCa diagnosis in the clinical setting.
Despite our small sample size PCA3 analysis of urinary sediments had diagnostic 
performance similar to that in previous studies.12, 14, 18 When exosomal RNA was 
analyzed, the levels of PCA3 and TMPRSS2-ERG were significantly higher after 
DRE. However, these biomarker levels in exosomes seemed to have an insufficient 
correlation with the prostate biopsy outcome. A hypothesis to explain this 
finding may be that urinary microvesicles from patients with PCa have a different 
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content than those from healthy donors and, therefore, they contain less RNA, as 
previously described by Nilsson et al.9 This would also explain the fact that more 
exosome samples than cell pellet samples had biomarker levels that were BDL. 
Notably, absolute exosomal PCA3 copy numbers showed no diagnostic value. 
However, when PCA3 levels were normalized to PSA levels in the exosomes, 
the diagnostic value improved. This is in agreement with the Progensa®PCA3 
test in whole urine, which is also based on the PCA3/PSA ratio. Since PSA mRNA 
expression is relatively constant in normal prostate cells and PCa cells, PSA mRNA 
expression is used for normalization to noncancerous prostate cells.12, 19 
Our control group (negative biopsies) can be considered a limitation since it 
was not representative of healthy men in the normal population. Patients were 
selected for prostate biopsies based on increased PSA and/or abnormal DRE. 
Thus, they were at higher risk for a false-negative biopsy outcome than healthy 
peers. Diagnostic data might have been biased due to this limitation.
CONCLUSIONS
Comparative analysis of biomarkers in urinary sediment (cell pellets) and 
exosomes showed that exosomes seem to be a more robust source of biomarkers, 
although exosomes have lower analytical sensitivity. Furthermore, DRE resulted 
in higher biomarker levels in first catch urine for cell pellets and exosomes. 
However, the diagnostic performance of PCA3 in exosomes appeared different 
from that in cell pellets, i.e. PCA3 mRNA levels had to be normalized to PSA 
mRNA to achieve diagnostic improvement. Although we report that measuring 
biomarkers in exosomes is feasible and results seem promising, clinical usefulness 
and diagnostic value must be prospectively explored in larger cohorts.
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ABSTRACT
Background 
To reduce overdiagnosis and overtreatment, a test is urgently needed to detect 
clinically significant prostate cancer (PCa). 
Objective 
To develop a multimodal model, incorporating previously identified messenger 
RNA (mRNA) biomarkers and traditional risk factors that could be used to identify 
patients with high-grade PCa (Gleason score ≥7) on prostate biopsy. 
Design, setting, and participants
In two prospective multicenter studies, urine was collected for mRNA profiling 
after digital rectal examination (DRE) and prior to prostate biopsy. The multimodal 
risk score was developed on a first cohort (n = 519) and subsequently validated 
clinically in an independent cohort (n = 386). 
Outcome measurements and statistical analysis 
The mRNA levels were measured using reverse transcription quantitative 
polymerase chain reaction. Logistic regression was used to model patient risk 
and combine risk factors. Models were compared using the area under the curve 
(AUC) of the receiver operating characteristic, and clinical utility was evaluated 
with a decision curve analysis (DCA). 
Results and limitations
HOXC6 and DLX1 mRNA levels were shown to be good predictors for the detection 
of high-grade PCa. The multimodal approach reached an overall AUC of 0.90 (95% 
confidence interval [CI], 0.85–0.95) in the validation cohort (AUC 0.86 in the 
training cohort), with the mRNA signature, prostate-specific antigen (PSA) density, 
and previous cancer-negative prostate biopsies as the strongest, most significant 
components, in addition to nonsignificant model contributions of PSA, age, and 
family history. For another model, which included DRE as an additional risk factor, 
an AUC of 0.86 (95% CI, 0.80–0.92) was obtained (AUC 0.90 in the training cohort). 
Both models were successfully validated, with no significant change in AUC in the 
validation cohort, and DCA indicated a strong net benefit and the best reduction 
in unnecessary biopsies compared with other clinical decision-making tools, such 
as the Prostate Cancer Prevention Trial risk calculator and the PCA3 assay. 
Conclusions
The risk score based on the mRNA liquid biopsy assay combined with traditional 
clinical risk factors identified men at risk of harboring high-grade PCa and resulted 
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in a better patient risk stratification compared with current methods in clinical 
practice. Therefore, the risk score could reduce the number of unnecessary 
prostate biopsies. 
Patient summary
This study evaluated a novel urine-based assay that could be used as a noninvasive 
diagnostic aid for high-grade prostate cancer (PCa). When results of this assay are 
combined with traditional clinical risk factors, risk stratification for high-grade PCa 
and biopsy decision making are improved.
INTRODUCTION
Prostate cancer (PCa) is the second most frequently diagnosed cancer among 
men worldwide, with an estimated 1.1 million new cases and 307 500 deaths 
in 2012.1 With the introduction of serum prostate-specific antigen (PSA) testing 
in the 1990s, the incidence of PCa has increased. PSA testing has also led to 
an increased number of unnecessary biopsies and the diagnosis of clinically 
insignificant tumors that would not have been life threatening (i.e. potential 
overtreatment). This is particularly the case in a PSA gray zone <10.0 ng/ml, at 
which 65–70% of men have a negative biopsy result.2 Men with indolent disease 
who undergo treatment may experience complications without reducing their 
risk of dying from PCa.3 Albertsen et al. showed that men with Gleason score (GS) 
8–10 PCa have a relatively high probability of dying from PCa within 10 yr (12.1%), 
whereas this risk is minimal for men with low-grade disease.4 
The major challenge is to improve the detection of clinically significant or 
high-grade PCa in an early stage. Both overdiagnosis and overtreatment could 
be reduced if PCa-specific biomarkers could accurately distinguish indolent from 
aggressive tumors. Ideally the biomarkers could be measured in a sample that 
could be obtained noninvasively (e.g. in urine). The urinary test based on the 
prostate cancer antigen 3 (PCA3) gene (Progensa PCA3; Hologic Inc, Marlborough, 
MA, USA) is the only molecular diagnostic test approved by the US Food and 
Drug Administration for the detection of PCa in urine.5, 6 PCA3 was identified as 
a gene encoding a long noncoding RNA that is consistently upregulated in PCa.7, 
8 PCA3 was shown to be of value in PCa detection; however, the relation with 
tumor aggressiveness and thus prognostic value remains controversial.9-11 New 
biomarkers for PCa detection are the blood-based Prostate Health Index (PHI) 
and the four-kallikrein panel.12-17 Studies describing head-to-head comparison of 
these markers showed that PHI outperforms PCA3 in the prediction of significant 
PCa.17 
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Previous studies have shown the potential of noninvasive urinary biomarkers to 
accurately predict the presence of high-grade disease and thus aid in decision 
making regarding further diagnostic evaluations (e.g., prostate biopsies or imaging) 
and treatment while avoiding unnecessary biopsies. Leyten et al. described a 
stepwise approach for the identification and selection of new biomarkers using 
messenger RNA (mRNA) expression profiling.18 A panel measured in urinary 
sediments predicted a GS≥7 on prostate biopsy. The test, based on detecting 
increased mRNA levels of homeobox C6 (HOXC6), distal-less homeobox 1 (DLX1), 
and tudor domain containing 1 (TDRD1), was shown to have independent 
additional value to PSA for predicting high-grade PCa on biopsy. HOXC6, DLX1, and 
TDRD1 may be involved in the onset of PCa and are associated with high-grade 
PCa.18 In this study, homeobox C4 (HOXC4) was also included because it was 
shown to be overexpressed in urine sediments and is transcribed from the same 
transcription unit as HOXC6.18 
The aim of this study was to validate the gene panel-based mRNA test performed 
on whole urine and to develop a model combining molecular profiling with 
traditional clinical risk factors that could be used to identify patients accurately 
with high-grade PCa (GS≥7) on prostate biopsy. To optimize patient management 
and clinical utility, all relevant information to make the most accurate assessment 
for each patient should be taken into account. Multimodal risk assessment 
approaches have been developed that combine multiple information sources into 
an overall optimal risk prediction for each individual patient. One such score is 
the Prostate Cancer Prevention Trial risk calculator (PCPTRC), which combines 
PSA with digital rectal examination (DRE), race, family history, age, and whether a 
patient had a previous biopsy.19 Patient management and risk assessment benefit 
from combining different complementary information sources into one coherent 
risk score because no single marker can obtain a similar performance on its own.19, 
20 The optimal diagnostic model was validated in urine samples from a second, 
independent cohort to ensure robustness of the proposed risk score.
MATERIALS AND METHODS
Study population
In two prospective multicenter studies, men who were scheduled for (initial or 
repeat) prostate biopsies, based on elevated PSA levels (≥3 ng/ml), abnormal 
DRE, or a family history of PCa, were consecutively included. Urine samples were 
collected after a standardized DRE consisting of three strokes per lobe.6 Subjects 
were enrolled from six urology clinics in the Netherlands (Radboud University 
Medical Center Nijmegen, ZGT Hospital Hengelo, AMC University Medical Centre 
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Amsterdam, CWZ Hospital Nijmegen, St. Elisabeth Hospital Tilburg, and Scheper 
Hospital Emmen) between September 2009 and July 2011 (clinical trial A) and 
between July 2011 and September 2014 (clinical trial B). Exclusion criteria were 
a history of PCa, medical therapy known to affect PSA levels, prostate biopsy 
within 3 months prior to enrollment, and invasive treatment for benign prostate 
hyperplasia within 6 months prior to enrollment. Transrectal ultrasound (TRUS)–
guided prostate biopsy was performed, with a median of 10 cores (interquartile 
range: 10–10) per patient, and evaluated per each hospital’s standard procedure 
and by local pathologists. 
The institutional review boards of all of the hospitals approved the study 
protocols, and written informed consent was obtained from each participant. 
Test results were not provided to the clinical sites for patient care, and the 
laboratory technicians who performed the biomarker tests were blinded for 
patient characteristics. The developmental study and the validation study were 
both performed in accordance with the Standards for Reporting of Diagnostic 
Accuracy criteria.21
Sample collection and processing
Approximately 30 ml of first voided urine was collected in a collection cup 
after DRE. Urine was immediately transferred into a urine specimen transport 
tube (Hologic Inc), and samples were shipped at room temperature to a central 
laboratory and stored  at -80 °C.
Laboratory-developed test development
In the discovery and initial validation study, urinary sediments were used as 
described by Leyten et al.18 Fixed whole urine was used as substrate to further 
optimize and standardize the assay. Assays were performed using a prototype 
amplification kit (Labo Biomedical Products BV, Rijswijk, The Netherlands). In 
short, RNA was isolated out of 1 ml urine using the MagNA Pure 96 instrument 
(Roche Life Science, Indianapolis, IN, USA). Subsequently, RNA levels of HOXC4, 
HOXC6, TDRD1, DLX1, KLK3, and PCA3 were determined using one-step reverse 
transcription quantitative polymerase chain reaction. The KLK3 gene, encoding for 
PSA, is a kallikrein serine protease and used as a reference for relative biomarker 
quantitation using the ΔΔCt method.22
Statistical analysis
Statistical analyses were performed with SPSS v.20.0 (IBM Corp., Armonk, NY, 
USA) and R v.3.2.1 (R Foundation for Statistical Computing, Vienna, Austria). 
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For comparison of continuous variables, the Welch t test was used or the 
Mann-Whitney-Wilcoxon test as a nonparametric alternative. A binomial or Fisher 
exact test was applied to compare proportions. Because mRNA levels of these 
biomarkers are continuously increasing with patient risk, their performance was 
assessed and evaluated as area under the curve (AUC) of the receiver operating 
characteristic. The 95% confidence intervals (CIs) and comparisons of AUCs were 
determined using DeLong’s method as implemented in the R package pROC.23 The 
combination and predictive value of multiple risk factors was modeled by logistic 
regression analysis, resulting in a continuous risk score that can also be evaluated 
with the AUC method. The main models aimed to identify high-grade (GS≥7) PCa, 
using low-grade (GS≤6), likely insignificant, cancer and men with a PCa-negative 
diagnosis as the control group. The logistic regression model was then applied to 
estimate the probability of detecting no, low-grade, or high-grade PCa on biopsy. 
Clinical utility was assessed with decision curve analysis (DCA) in R.24
RESULTS
Patient characteristics
A total of 905 urine samples were collected in two independent prospective 
clinical trials (cohort A: n = 519; cohort B: n = 386). Table 1 summarizes the 
patient characteristics. In cohort A, 212 of 519 men (40.8%) had a positive biopsy 
outcome, of which 109 men (51.4%) had high-grade (GS≥7) PCa, compared with 
181 of 386 men (46.9%) and 90 men (50.0%), respectively, in cohort B. More men 
had undergone at least one prior biopsy, and more men had an abnormal DRE 
outcome in cohort A. The other baseline characteristics showed no statistically 
significant differences between both cohorts.
Selection of the most informative messenger RNA biomarkers
The performance of individual biomarkers to predict high-grade PCa on biopsy 
was compared. In addition to the AUC, specificity, negative predictive value 
(NPV), and positive predictive value (PPV) were determined at a fixed sensitivity 
of approximately 90%, with HOXC6 as the strongest individual marker (Table 
2). Next, the best complementary marker for HOXC6, the strongest performing 
individual marker in terms of AUC, was identified. HOXC6 and HOXC4 were strongly 
correlated, with a Pearson correlation coefficient of 0.80, indicating limited 
complementarity. To determine whether DLX1 or TDRD1 could complement the 
performance of either HOXC6 or HOXC4, models were generated based on the 
sum of the ratios. The combination of HOXC6 and DLX1 had the best performance 
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with an AUC of 0.76 (95% CI, 0.71–0.81). The addition of other markers to this 
model did not result in further performance improvement. This combination was 
successfully validated in cohort B, with an AUC of 0.73 (95% CI, 0.67–0.78; p = 0.4 
difference of AUCs) (Figure 1).
Table 1.	Patient	characteristics
DRE:	 digital	 rectal	 examination;	 GS:	 Gleason	 score;	 IQR:	 interquartile	 range;	 NA:	 not	
available;	PCa:	prostate	cancer;	PSA:	prostate-specific	antigen;
PSAD:	prostate-specific	antigen	density;	TRUS:	transrectal	ultrasound.
Because	race	data	were	not	recorded,	based	on	general	hospital	records,	it	was	assumed	
that	>95%	of	this	study	population	was	white.
a	Number	of	evaluable	samples	based	on	a	minimal	 level	of	KLK3	reference	messenger	
RNA,	as	described	in	the	text.
b	The	p	value	when	only	taking	into	account	those	patients	for	which	the	information	was	
available.	When	under	the	assumption	that	the	vast	majority	of
patients	for	whom	this	information	was	not	available,	have	no	family	history	of	PCa,	the	
difference	is	not	statistically	different	(p	=	0.6).
c	For	one	subject	the	total	GS	could	not	be	determined,	but	at	least	a	Gleason	4	component	
was	present.
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Table 2.	Biomarker	models	used	for	the	development	with	cut-off	and	clinical	performance
AUC:	area	under	the	curve;	NPV:	negative	predictive	value;	PPV:	positive	predictive	value;	
Se:	sensitivity;	Sp:	specificity.
Figure 1. Receiver operating 
characteristic curves for HOXC6 and 
DLX1 messenger RNA expression 
levels in urine in the training and 
validation cohorts.
Informative rate
KLK3 was used as a measure for the presence of prostate-derived transcripts, 
and the expression level was about 1000-fold higher compared with biomarker 
mRNAs. A minimum threshold of 10 000 copies was set for the expression of 
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this gene, and samples without sufficiently high biomarkers signal with fewer 
copies of the reference gene were considered nonevaluable because of fear of 
false-negative assay results (Table 1).
Combining risk factors for optimized detection of high-grade prostate cancer
All available molecular and traditional risk factors were combined in a logistic 
regression model to determine their relative contribution and importance to 
predict the presence of high-grade PCa on biopsy. A first logistic regression model 
was built using age, PSA, PSA density (PSAD), family history of PCa, DRE, history 
of prostate biopsy, and HOXC6 and DLX1 expression levels, and it was evaluated 
in cohort A. To account for differences in scale, transformations were investigated 
for some variables. A log-transformation for PSA, HOXC6 and DLX1 expression 
levels, and PSAD improved the overall model’s performance. The output from the 
model was a risk score based on all available information.
Model 1 included all variables and reached an AUC of 0.90 (95% CI, 0.87–0.93) 
for high-grade PCa (Figure 2A and Table 3). The biopsy outcome prediction had 
a significant contribution from DRE (p < 0.001), PSAD (p = 0.004), HOXC6 and 
DLX1 expression levels (p = 0.003), history of previous cancer-negative biopsies 
(p = 0.02), however not from PSA (p = 0.08), family history (p = 0.15), or age (p = 
0.7). To verify whether the variables that did not have a significant contribution in 
the model did not result in overfitting, a backward elimination strategy (variables 
with p > 0.05) was applied until the model consisted only of significant variables. 
This model included DRE, PSAD, previous cancer-negative biopsies, and HOXC6 
and DLX1 expression levels and had an AUC of 0.89 (95% CI, 0.86–0.93).
Table 3. Odds	ratios,	95%	confidence	intervals,	and	p	values	for	risk	factors	as	obtained	in	
the training cohort during development of the risk score
CI:	confidence	interval;	DRE:	digital	rectal	examination;	OR:	odds	ratio;	PSA:	prostate-specific	
antigen;	PSAD:	prostate-specific	antigen	density.
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A
B
Figure 2. Receiver operating 
characteristic curves comparing (A) 
model 1 and (B) model 2 in cohorts 
A and B with the Prostate Cancer 
Prevention Trial risk calculator 
(PCPTRC) alone and the combined 
PCPTRC and PCA3.
A second model was developed excluding diagnostic DRE results, to avoid 
variables subject to interobserver variability. Model 2 reached an AUC of 0.87 
(95% CI, 0.83–0.91), which was significantly lower than that of model 1 (p = 0.009 
for comparison of AUCs) (Figure 2B and Table 3).
Clinical validation
In cohort B, an AUC of 0.86 (95% CI, 0.80–0.92) (Figure 2A) was obtained for 
model 1. The proposed model proved to be a robust predictor for the detection 
of high-grade PCa, as illustrated by a successful validation in this independent 
cohort by a direct comparison with cohort A (p = 0.3 for the difference between 
AUCs). In cohort B, model 2 reached an AUC of 0.90 (95% CI, 0.85–0.95), also 
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not significantly different from the AUC obtained in the training cohort (p = 0.4) 
(Figure 2B). In the validation cohort, model 2 significantly outperformed model 
1 (p = 0.033 for the difference between AUCs), supporting the interobserver 
variability hypothesis. To further validate the contribution of HOXC6 and DLX1, 
model 2 was compared with a model that only incorporated traditional clinical 
risk factors (AUC: 0.87; 95% CI, 0.81–0.93). The addition of the mRNA markers to 
the model resulted in a significantly higher AUC (p = 0.018). Similarly, PCA3 was 
added to the clinical risk factors model and trained in cohort A; however, this did 
not result in a significant improvement of the AUC on validation in cohort B (AUC: 
0.88; 95% CI, 0.82–0.94; p = 0.2).
Clinical applicability and validity
The performance characteristics of these models were evaluated relative to 
current, clinically relevant methods in the independent validation cohort B. The 
PCPTRC v.2, based on a model incorporating PSA with other traditional clinical risk 
factors, was used as the main benchmark. Merely as a reference for the predictive 
value and complementarity of models including biomarkers and clinical risk factors, 
PCPTRC was combined with PCA3. The AUC for the PCPTRC predicting the chance 
of high-grade PCa was 0.77 (95% CI, 0.71–0.83), indicating that the mRNA-based 
risk score as incorporated in model 1 or 2 provided a significant improvement (p 
= 0.015 and p < 0.001, respectively) (Figure 2). The AUC for PCPTRC combined 
with PCA3 was 0.80 (95% CI, 0.74–0.85), which was significantly lower than the 
AUC of model 2 (p = 0.18 and p = 0.007 for the comparison of AUCs with models 
1 and 2, respectively). Finally, AUCs of 0.90 (95% CI, 0.85–0.96) and 0.93 (95% 
CI, 0.89–0.97) with model 1 and 2, respectively, to detect high-grade PCa were 
observed when potentially undergraded GS≤6 PCa samples were removed from 
cohort B, only using the PCa-negative men as controls.
This risk score showed a significant increase across all groups of men with, 
respectively, no PCa, GS≤6, and GS≥7 PCa (all p < 0.001) (Figure 3A). A Spearman 
correlation coefficient of 0.61 was observed (p < 0.001), indicating a strong positive 
relationship between the risk score and biopsy outcome. For practical purposes, 
the outcome of the risk score was translated into the chance of observing no 
PCa, GS≤6, or GS≥7 PCa (Figure 3B), offering a direct relation to the test’s positive 
predictive value (PPV) and negative predictive value (NPV).
To further improve the applicability of the model in clinical practice, PSAD was 
substituted for DRE-based prostate volume, resulting in three classes, that is, 
small (<30 ml), medium ( ≥30 and <60 ml), and large (≥60 ml). Medium and large 
prostates resulted in a decrease of the risk score relative to small prostates. 
60
Interestingly, the AUCs were not significantly lower based on these categorical 
volume assessments (AUC: 0.85, 95% CI, 0.79–0.92, p = 0.3 for model 1; AUC: 
0.88, 95% CI, 0.82–0.94, p = 0.092 for model 2).
A
B
Figure 3. Relation between the risk score 
and biopsy outcome. (A) Box plot shows 
increasing levels of the risk score when 
finding no prostate cancer (PCa), low-grade 
PCa, or high-grade PCa on biopsy that was 
translated into (B) the likelihood of having 
a particular biopsy outcome in relation to 
the risk score.
Performance in the prostate-specific antigen grey zone
The performance of the risk score was evaluated in the 264 men with low (<10 
ng/ml) serum PSA levels from cohort B, of which 226 men had no or low-grade 
PCa (85.6%). The risk score remained the strongest predictor in this group of men 
in the PSA gray zone with an AUC of 0.78 (95% CI, 0.68–0.88) for model 1 and an 
AUC of 0.85 (95% CI, 0.77–0.93) for model 2, compared with PCPTRC with an AUC 
of 0.66 (95% CI, 0.57–0.75; p = 0.071 and p = 0.001). Again merely as a reference, 
the addition of PCA3 to the PCPTRC to compensate for PSA yielded an AUC of 0.72 
(95% CI, 0.64– 0.80), which was significantly lower than the AUC of model 2 (p = 
0.5 and p = 0.033 for models 1 and 2, respectively).
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Clinical utility
To evaluate the clinical utility of the risk score, a DCA was performed on the 
independent cohort B and compared with other decision-making tools used 
in clinical practice, merely for reference purposes (Figure 4). Test harm was 
incorporated in the DCA for all evaluated tools, assuming that for first-line 
diagnostics no more than 50 patients should be evaluated to identify one 
high-grade PCa. Compared with the PCPTRC, and a model combining the PCPTRC 
with PCA3, the risk score, especially for model 2, clearly resulted in the largest 
net benefit in terms of accurately detecting men with high-grade PCa, even for 
those men who are very risk averse (Figure 4A), while at the same time maximally 
reducing the unnecessary biopsy rate (Figure 4B). From a practical point of view, 
at a cut-off with an NPV of 98% for GS≥7 PCa, a total reduction of biopsies by 42% 
and a decrease of the unnecessary biopsies by 53% were obtained.
            A
            B
Figure 4. Decision curve analysis 
illustrating the overall clinical utility 
of models 1 and 2 compared with the 
Prostate Cancer Prevention Trial risk 
calculator (PCPTRC) alone and the PCPTRC 
and PCA3 combined in the validation 
cohort. Clinical utility of the risk score 
is demonstrated by (A) the overall net 
benefit in detecting high-grade prostate 
cancer without performing unnecessary 
biopsies and (B) the net reduction in 
interventions without missing any of 
these high-grade cancers.
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DISCUSSION
New promising PCa-specific biomarkers have been identified in many studies; 
however, to date, only a few biomarkers have reached clinical practice. The 
main challenge is to validate the performance of the biomarkers in a clinical 
cohort independently and to demonstrate the clinical utility clearly. Leyten et 
al. selected a promising urinary mRNA panel for the prediction of high-grade 
PCa (GS≥7) on prostate biopsy.18 In the current prospective multicenter study, a 
model was developed combining two of the most promising biomarkers, HOXC6 
and DLX1, with traditional risk factors, most notably PSAD and DRE but also PSA, 
family history of PCa, and age, into one logistic regression model. The risk score 
derived from this model was the best performing assay to detect high-grade PCa 
on prostate biopsy and was successfully validated in an independent prospective 
cohort. A second model, excluding DRE as a risk factor because of potential 
interobserver variability in its assessment, was also validated successfully. The 
fact that, compared with the first model, the second model had a higher AUC 
in the validation cohort, but a lower AUC in the training cohort, is most likely a 
reflection of this interobserver variability. Hence the inclusion of DRE as a risk 
factor should be carefully considered. The models significantly outperformed the 
PCPTRC and PCA3. This was also true for the model that included HOXC6 and 
DLX1, age, PSA, PSAD, family history of PCa, and a history of prostate biopsy when 
compared with a combination of PCPTRC and PCA3. The addition of HOXC6 and 
DLX1 mRNA markers showed an improved patient stratification over the model 
with only the traditional clinical risk factors, which was not the case for PCA3. 
Although the traditional clinical risk model resulted in a relatively high AUC by 
itself, it was mainly driven by PSAD. Interestingly, the model did not depend on 
PSAD as such, which was illustrated by the similar performance of a model that 
included categorized DRE volume (small, medium, and large prostate size) rather 
than PSAD.
In the current study, mRNA assays were performed on whole urine samples, 
which is preferred for biomarker analysis because it does not require 
labor-intensive, time-consuming urine-processing procedures, and mRNA yield is 
not compromised.25
In the PCPT, Thompson et al. reported the diagnosis of PCa in 15.2% of men with a 
PSA level ≤4 ng/ml, of which 14.9% had high-grade disease.26 This risk was very low 
for patients with a PSA level <1 ng/ml but increased to 9.4% in patients with a PSA 
between 3 and 4 ng/ml, that is, one could conclude that the currently accepted 
risk of missing significant cancers using PSA is up to 9.4% when a threshold of 4 
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ng/ml is used or 5.7% when a threshold of 3 ng/ml is used.27 The clinical utility of 
the risk score was vastly beneficial, as illustrated by the potential higher detection 
rate of high-grade PCa while lowering the number of unnecessary repeat biopsies 
when adopting this model, in particular when compared with a model including 
PCPTRC and PCA3; however, it should be noted that the latter was not developed 
specifically for high-grade cancer.
The risk score enables objective clinical risk assessment and patient management, 
but it also compensates for risk factors that are, by their very nature, subjective 
or subject to interobserver variability. In this study, this is particularly true for 
DRE; however, even when included, the risk score remained the strongest, most 
significant predictor of patient risk compared with other clinically relevant risk 
assessment algorithms, such as PCA3 and the PCPTRC.
The main limitations of this study are the lack of centralized pathology and the 
fact that the gold standard for PCa diagnosis, namely, TRUS-guided biopsy, not 
only has a false-negative rate of approximately 20%,28, 29 but it also has difficulty 
detecting PCa in the anterior (and apical parts) of the prostate.30 Because only 16% 
of the cohort was composed of men with at least one previous cancer-negative 
biopsy, it would be interesting to study the repeat biopsy setting specifically.
CONCLUSIONS
The two-gene risk score combining HOXC6 and DLX1 mRNA expression levels 
with traditional clinical risk factors (i.e. PSAD, DRE, PSA, age, history of prostate 
biopsy, and family history) is able to detect high-grade, clinically significant PCa 
accurately and could therefore be used in decision making, reducing the number of 
unnecessary prostate biopsies and potential overtreatment. This newly developed 
risk score significantly outperforms the PCPTRC, a multimodal risk assessment 
approach, and improves the diagnosis and management of PCa patients. Future 
research might indicate that additional parameters could further optimize the 
diagnosis of high-grade PCa without contributing to the high unnecessary biopsy 
rate.
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ABSTRACT
Objective: To assess the cost-effectiveness of a new urinary biomarker-based risk 
score (SelectMDx) to identify patients for transrectal ultrasound-guided biopsy 
(TRUSGB) and to compare this with the current standard of care (SOC), using only 
prostate-specific antigen (PSA) to select for TRUSGB.
Materials and methods: A decision tree and Markov model were developed to 
evaluate the cost-effectiveness of SelectMDx versus SOC in men with a PSA >3 ng/
ml. Transition probabilities, utilities and costs were derived from literature and 
expert opinion. Cost-effectiveness was expressed in quality-adjusted life years 
(QALYs) and healthcare costs of both diagnostic strategies, simulating the course 
of patients over a time horizon representing 18 years. Deterministic sensitivity 
analyses were performed to address uncertainty in assumptions.
Results: A diagnostic strategy including SelectMDx with a cut-off chosen at a 
sensitivity of 95.7% for high-grade PCa resulted in savings of €128 and a gain of 
0.025 QALY per patient compared to the SOC strategy. The sensitivity analyses 
demonstrated that the disutility assigned to active surveillance had a high 
impact on the QALYs gained and the disutility attributed to TRUSGB only slightly 
influenced the outcome of the model.
Conclusion: Based on the currently available evidence, the reduction of 
overdiagnosis and overtreatment due to the use of the SelectMDx test in men 
with PSA>3 ng/ml may lead to a reduction in total costs per patient and a gain in 
QALYs.
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INTRODUCTION
The standard of care (SOC) in prostate cancer (PCa) diagnostics relies mainly 
on serum prostate-specific antigen (PSA) testing and digital rectal examination 
(DRE). Subsequently, a systematic 10-12 core transrectal ultrasound-guided 
biopsy (TRUSGB) is the gold standard to obtain prostate pathology for a definite 
diagnosis. The pitfall with this approach is, unfortunately, the low specificity of PSA 
for (high-grade) PCa, leading to a considerable number of unnecessary biopsies. 
These men are therefore unnecessarily exposed to potential complications of 
this procedure, such as infections, lower urinary tract symptoms (LUTS) and 
hematuria.1 Moreover, this drawback of PSA testing facilitates the diagnosis of 
clinically insignificant tumours, which in turn can lead to potential overtreatment.2, 
3 Besides the fact that these men are unnecessarily exposed to the potential side 
effects of invasive treatment, being diagnosed with cancer brings a psychological 
burden to the patient.4 Finally, overdiagnosis and overtreatment also have broader 
implications, resulting in an increase in healthcare costs for the community.5 
PSA screening studies demonstrated a reduction in PCa mortality attributable 
to PSA testing, however, the benefit of this screening was diminished by loss of 
quality-adjusted life years (QALYs) owing to long-term effects after diagnosis.4, 6
Proper patient selection for prostate biopsy with a focus on significant disease 
might improve the diagnostic pathway, reduce the number of unnecessary 
biopsies and decrease overtreatment. A recently published new urinary molecular 
biomarker-based risk score (SelectMDx, MDxHealth, Inc.) was developed to 
identify patients that are at risk of harboring high-grade PCa (Gleason score 
≥7).7 This risk score is based on the urinary HOXC6 and DLX1 mRNA signature in 
combination with serum PSA, PSA density and other clinical risk factors such as age, 
prior cancer-negative biopsies, DRE and family history. The multimodal approach, 
including both traditional and molecular risk factors, reached an area under the 
curve (AUC) of 0.86 (95% confidence interval [CI], 0.80-0.92) for the prediction 
of high-grade PCa upon biopsy. In addition, an evaluation of clinical utility using 
decision curve analysis indicated a strong net benefit to detect high-grade disease 
and a significant reduction in the number of unnecessary biopsies.7 
Although this new risk score will be subject to additional clinical validation in 
further prospective trials, cost-effectiveness and quality of life (QoL) effects based 
on the diagnostic performance and clinical consequences should also be addressed 
in the current light of growing health care costs. Therefore, the objective of this 
study was to evaluate costs, QoL and survival effects when using the SelectMDx 
risk score in men with a PSA score >3 ng/ml and comparing this to the SOC in the 
diagnostic pathway for PCa.
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MATERIALS AND METHODS
Model development
A decision analytical model was constructed which displays a mathematical 
method to weigh risks, benefits and costs of clinical strategies (TreeAgePro 
2014). A decision tree represented two diagnostic and PCa treatment pathways 
(Figure 1). Subsequently, a decision-analytic Markov model representing the 
patient follow-up was developed. Each cycle in the model was set to one year, 
meaning that the patients in the cohort had a probability to move to a different 
health state after each year. One-way sensitivity analyses were performed on 
the input parameters of the model. After the health event radical prostatectomy 
(RP) or radiotherapy (RT), patients moved to long-term complications (i.e. 
post-radiotherapy complications, erectile dysfunction and incontinence). The 
state after long-term complications or watchful waiting (WW) was death. The 
combined model was used to evaluate costs, QoL and survival effects of two 
different strategies.  
Figure 1. Decision tree structure for the SOC and SelectMDx strategy.
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The first strategy consisted of the current SOC in which patients with an elevated 
PSA (>3 ng/ml) undergo a systematic TRUSGB. In case of negative biopsies, 
follow-up will be performed by the general practitioner. When a patient is 
diagnosed with a high-grade tumour (Gleason score ≥7) the patient will undergo 
a radical prostatectomy (RP), radiation therapy (RT) or watchful waiting (WW), 
while active surveillance (AS) will be the main option if a low-grade PCa is detected 
(Gleason score ≤6). However, for the latter group of patients, curative treatment 
(RP or RT) can be an alternative. 
In the second, experimental strategy, patients with an elevated PSA (>3 ng/ml) 
are subsequently evaluated with a SelectMDx test. In case the SelectMDx test 
is positive, the patient will undergo a systematic TRUSGB. When a high-grade or 
low-grade tumour is detected the same treatment options from the first strategy 
can be followed. If no tumour is found on biopsy or if the SelectMDx test is negative, 
the patient will be followed up by the general practitioner. In both strategies it was 
assumed that patients with a false-negative biopsy or false-negative SelectMDx 
test would eventually be detected during the continued follow-up. In the model it 
was assumed that these patients will be detected based on clinical symptoms and 
therefore are beyond localized disease and will not qualify to undergo curative 
treatment. 
Transition probabilities
Within the constructed model the cohort of patients moves through different 
health states according to a set of transition probabilities. The probability of 
correctly dividing patients with expected high-grade cancer from patients without 
cancer or low-grade cancer was based on the accuracy of a subset of patients from 
the SelectMDx validation study (n=619), that met all clinical input parameters 
(PSA, PSA density, age, family history, prior biopsy and DRE).7 For the base case 
analysis a cut-off point in the SelectMDx risk score was used to divide patients 
with expected high-grade cancer from patients without cancer or low-grade 
cancer. This cut-off point resulted in a sensitivity for high-grade PCa of 95.7% and 
a specificity for low-grade PCa and no PCa of 33.6% and 60.8%, respectively. 
Remaining input data for the model were derived from clinical studies and expert 
opinion as shown in Table 1.7-9 PCa specific survival was assumed similar for both 
RP and RT in case of high-grade PCa.10 General survival data was based on the 
annual survival of the Dutch population from the age of 65 years 11 (online data). 
72
Table	1.	Transition	probabilities
PCa:	 prostate	 cancer;	 HG:	 high-grade;	 LG:	 low-grade;	 RP:	 radical	 prostatectomy;	 RT:	
radiotherapy;	WW:	watchful-waiting;	 base	 case:	missing	 a	 LG-PCa	 has	 no	 detrimental	
effect	 on	 survival;	 scenario	 case:	missing	 a	 LG-PCa	will	 affect	 survival	 in	 a	 deleterious	
manner.
Effectiveness
Effectiveness was measured in terms of QALYs. To arrive at QALYs, health-related 
QoL was expressed as a utility value on a scale from 0 (death) to 1 (perfect health), 
and the life years lived with this utility. The utility scores used for calculation of the 
QALYs are displayed in Table 2. For the first year the utility scores were based on 
the performed biopsy, the diagnosis of PCa and the applied treatment. After the 
first year, utility scores were attached to the health events no problems, long-term 
complications, AS or death. The disutility for AS and long-term complications were 
assumed to be for lifetime. For the latter, the disutility estimate was calculated as 
a mean disutility for both patients with and without long-term complications. 
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Table 2.	Disutility	estimates
PCa:	prostate	cancer;	RP:	radical	prostatectomy;	RT:	radiotherapy;	AS:	active	surveillance	
The	 disutility	 estimate	was	 calculated	 as	 a	mean	 disutility	 for	 both	 patients	 with	 and	
without	long-term	complications.
Cost information
Costs for biopsy, treatment, long-term complications and AS were incorporated 
using a health care perspective (Table 3). These costs were based on cost 
calculations from the Radboud University Medical Center (Radboudumc, 
Nijmegen, The Netherlands) in the year 2015. To complete the total prostate 
biopsy costs, mean complication costs were integrated in total biopsy costs. 
Furthermore, early and late complications of RP and RT were also included (i.e. 
incontinence, gastro-intestinal toxicity). To reflect the effects and costs over the 
time horizon of the analysis, QALYs and costs were respectively discounted by 
1.5% and 4% according to Dutch guidelines 12 (online data).     
Data analysis
The course of patients in both strategies were simulated over a time horizon 
representing 18 years, based on the median follow-up time of survival data for 
PCa patients, described in a series by Bill-Axelson.8 Patients entered the model at 
a median age of 65 years. The impact of different consequences using SelectMDx 
were analyzed. Effects were expressed in terms of missed high-grade tumours, 
prevented biopsies, prevented treatment of low-grade cancers and the related 
differences in costs and QALYs. The effects were determined both per patient and 
for the population, accounting for the 17.177 patients annually at risk for localized 
PCa (stage T1/T2) in the Netherlands 13, 14 (online data). Analysis was done for 
two scenarios. In the base case scenario it was assumed that missing a low-grade 
tumour had no detrimental effect on survival, while in the alternative scenario 
finding a low-grade tumour resulted in an absolute risk reduction of dying from 
PCa of 3.8% due to treatment.8, 15, 16 Subgroup analysis was performed for men 
with PSA levels in a grey zone (3-10 ng/ml), since PSA is less directive for clinical 
outcome in this particular group. Moreover, the disutility estimates of biopsy and 
AS (Table 2) were assessed in sensitivity analyses. These estimates were evaluated 
with the given disutility and without disutility. 
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Table 3. Cost data
TRUSGB:	 transrectal	 ultrasound-guided	 biopsy;	 RP:	 radical	 prostatectomy;	 RT:	
radiotherapy;	AS:	active	surveillance.
TRUSGB	 complications	 included	 infections	 and	 hospital	 stay;	 RP	 complications	
included	urinary	 incontinence;	 RT	 complications	 included	urinary	 incontinence	and	 late	
gastro-intestinal	complications.
Table 4. Costs	and	effects	in	the	base	case	scenario
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RESULTS
Cost-effectiveness of SelectMDx compared with SOC
In the SOC strategy a patient considered at risk for PCa (PSA >3 ng/ml) had a 
probability of 77% to undergo an unnecessary TRUSGB (no PCa or low-grade 
PCa), while in the SelectMDx strategy this was 36%. Therefore, 41% of these 
unnecessary biopsies could be prevented. The probability to find a low-grade 
PCa was reduced by 7% (Table 4). In comparison with the SOC strategy, using the 
SelectMDx test, patients had a 1% probability that a high-grade PCa was missed.  
In the base case the SelectMDx strategy lowered the costs with €128 per patient 
relative to the SOC strategy (€2983 versus €3110, respectively), with a net gain 
of 0.025 QALYs per patient (Table 4). This resulted in a net cost reduction of €2.2 
million and an overall gain of 429 QALYs per annual cohort. In the alternative 
scenario, assuming that finding a low-grade PCa will result in survival benefit, 
0.01 QALYs were gained and €129 saved per patient, in favor of the SelectMDx 
test. This resulted in a total number of 167 QALYs gained with similar overall cost 
savings as in the base case.
Cost-effectiveness in the PSA gray zone (3-10 ng/ml)
Subgroup analysis of patients with PSA levels between 3-10 ng/ml demonstrated 
a benefit for the SelectMDx test in the base case, with a QALY gain of 0.0326 and 
a cost reduction of €170 per patient (Table 4). In the alternative scenario this was 
0.0161 and €171 per patient, respectively.
Impact of the different consequences using SelectMDx
Missing high-grade PCa resulted in a loss of 0.011 QALYs relative to the SOC strategy. 
The prevention of biopsies due to the SelectMDx test saved €198 and gained 
0.0015 QALYs, however, this did not outweigh the extra costs of using SelectMDx 
and the loss of QALYs due to missed high-grade tumours. The prevention of 
revealing low-grade tumours (and the subsequent treatment or follow up with 
AS) had the highest impact on the outcome with €199 in saved costs and a net 
gain of 0.0345 QALYs. This made the SelectMDx a favorable strategy compared 
with SOC. 
Sensitivity analysis
The disutility assigned to AS patients demonstrated the highest impact on the 
QALYs. When AS was assumed not to influence the QoL, i.e. no disutility, the 
SelectMDx test gained 0.0025 QALYs per patient in the base case. However, in 
the alternative scenario, the SOC strategy was more effective with 0.013 QALYs 
per patient gained when AS did not influence the QoL. In the alternative scenario 
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analysis a disutility of at least 0.017 for AS will make the SelectMDx test more 
cost-effective compared to SOC. Treatment of low-grade PCa with RP or RT 
influenced both QALYs and costs. When all low-grade tumours were followed by 
AS, instead of treatment with RP or RT, the health gain with the SelectMDx test 
in the base case decreased to 0.0184, with a cost reduction of €7.51 per patient. 
When the postoperative recovery duration was set at 9 years instead of lifetime, 
this changed the net QALY gain per patient to 0.022 in favour of the SelectMDx 
strategy, relative to SOC. When also the active surveillance duration was changed 
to 7 years instead of lifetime, this changed the QALY gain per patient to 0.016, still 
in favour of the SelectMDx strategy. 
The disutility attributed to TRUSGB did only slightly influence the outcomes of 
the model. When no disutility for TRUSGB was assigned, the difference in QALYs 
between the strategies was 0.024, which was only slightly lower than in the base 
case analyses.
DISCUSSION
The current diagnostic strategy for PCa, based on PSA testing, is associated with 
a high number of unnecessary prostate biopsies and the detection of clinically 
insignificant tumours.5 This study demonstrated the potential cost-effectiveness 
of using SelectMDx as a second step diagnostic decision tool to opt for prostate 
biopsies in a group of patients potentially at risk for PCa. Net 41% of the biopsies 
could be saved compared to the SOC strategy, with a chosen cut-off for the test 
corresponding with a negative predictive value of 98% for high-grade PCa. The 
subsequent prevention of finding low-grade tumours, and the following treatment 
or AS, was a significant factor in the model. The major part contributing to the 
QALYs was determined by a loss of QoL in patients on AS, while reduction in radical 
treatment of low-grade tumours contributed in a lesser extent. The disutility 
attributed to AS was obtained from two studies from Heijnsdijk et al.4, 17 However, 
they based their assumption on theories described in previous studies, making the 
actual value to some extent uncertain. Sensitivity analysis demonstrated a health 
benefit using the SelectMDx test in case the disutility was set at least at 0.017 for 
AS patients. Both TRUSGB and SelectMDx test costs had an important influence 
on cost outcome, where reducing the SelectMDx test costs can be counted as a 
direct reduction in cost per patient. QALY and cost gain slightly decreased in the 
SelectMDx strategy when all men with low-grade tumours were assigned to AS 
(instead of 80%), which would be a preferable clinical situation.       
Since the validation study of the urinary molecular biomarker-based risk score used 
in this study was only recently published, this is the first study to compare this test 
with SOC from a healthcare perspective. However, recently several papers on the 
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cost-effectiveness of methods to reduce PCa overdiagnosis have been published.9, 
18, 19 De Rooij et al. suggested that MR imaging and MR-guided targeted biopsy 
is cost-effective compared to the SOC using TRUSGB, based on the reduction of 
overdiagnosis and overtreatment, while costs were almost equal between both 
strategies.9 Heijnsdijk et al. and Nichol et al. assessed the cost-effectiveness of 
prostate health index (phi) for prostate cancer detection and concluded that the 
use of PSA plus phi might reduce the number of negative biopsies and improve 
the cost-effectiveness of prostate cancer detection.18, 19 In future research it would 
be interesting to investigate the currently available prostate cancer diagnostic 
and prognostic modalities in a large prospective head-to-head comparison with 
respect to diagnostic accuracy and cost-effectiveness outcome.
Although results seem promising, this study is subject to certain limitations 
which should be taken into account. The fact that TRUSGB is used as the gold 
standard for PCa diagnosis might underestimate the actual number of patients 
with (high-grade) PCa.20, 21 Through the parallel comparison of both strategies in 
our study this would not affect the results directly, although it remains an ongoing 
limitation in PCa biomarker studies. The adverse pathology of low-grade tumours 
detected by TRUSGB, however, could potentially result in a lower sensitivity for the 
SelectMDx test and affect the results.22 Nonetheless, in the scenario analysis we 
assumed that there was a survival difference between revealed and unrevealed 
tumours, which means that if missed tumours were in fact high-grade tumours, 
this was accounted for in the model. This scenario analysis resulted in favor of the 
SelectMDx test, however the net gain in QALYs was lower compared to the base 
case scenario. 
Since the model was built on assumptions based on data from the literature and 
accuracy data was based on the validation study of the urinary biomarker-based 
risk score, outcome may not be irrespectively extrapolated to another population. 
Moreover, costs were based on Dutch healthcare standards and might therefore 
not be directly applicable in other countries. Yet, given the presentation of the 
used model input parameters in our study, these could be modified for a preferred 
situation, taking into account the clinical patient features and test accuracy of the 
modeled population. Also, different discount rates can be considered to reflect 
the effects and costs over the time horizon of the analysis. In our analysis, applying 
no discount or 5% discount for both QALYs and costs did not have a significantly 
influence on outcome. 
Considering no survival data was available for patients not eligible for curative 
treatment (primary locally advanced or metastatic disease), a conservative 
approach was chosen and cost-effectiveness was not separately modeled for 
this group. Assuming 4.3% of patients with high-grade PCa are missed by the 
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SelectMDx strategy, of which approximately 13% will not be eligible for curative 
treatment, the difference between both diagnostic strategies is only modest.23 
Taken into account that costs of androgen deprivation therapy will be lower than 
costs modeled for RP or RT, this would be in favor of the SelectMDx strategy.
Through this decision analytical model we attempted to reflect the 
cost-effectiveness of the novel urinary biomarker-based risk score in the current 
light of growing health care costs and the inability to rely on PSA testing alone, as 
this results in overdiagnosis and overtreatment. A major challenge however, will 
be the widespread clinical implementation of the new risk score, since deliberately 
avoiding diagnosis and subsequent treatment of low-grade tumours is currently 
subject to discussion and might be a barrier to overcome for both the patient and 
the clinician. Although results are in favor of the SelectMDx strategy, more research 
to further validate the accuracy and reliability of the biomarker-based risk score 
is needed, before the next challenging step in the direction of implementation in 
daily practice can be made. 
In conclusion, implementation of the SelectMDx test, in the patient population 
with PSA levels >3 ng/mL to select patients for TRUSGB, has the potential to 
improve QoL of patients, while saving costs compared to the current SOC. This 
biomarker-based risk score can reduce overdiagnosis and overtreatment with a 
minor chance of missing high-grade PCa. In our assessment, the expected loss in 
QALYs due to the latter was outweighed by the expected health gain, which was 
mainly caused by reducing the number of low-grade PCa diagnoses and to a lesser 
extent by the reduction in prostate biopsies. 
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ABSTRACT
Background 
To monitor systemic disease activity, the potential of circulating tumor cells 
(CTCs) bears great promise. As surrogate for CTCs we measured KLK3, PCA3 and 
TMPRSS2-ERG messenger RNA (mRNA) in the peripheral blood mononuclear cell 
(PBMC) fraction from a castration-resistant prostate cancer (CRPC) patient cohort 
and three control groups. Moreover, biomarker response to docetaxel treatment 
was evaluated in the patient group.
Methods
Blood samples from 20 CRPC patients were analyzed at four different time points 
(prior to docetaxel treatment, at 9 weeks, 27 weeks, and 2 months after treatment). 
Blood was drawn once from three control groups (10 age-matched men, 10 men 
under 35 years of age, 12 women). All samples were analyzed for KLK3, PCA3 and 
TMPRSS2-ERG mRNA by using a quantitative nucleic acid amplification assay with 
gene-specific primers in the complementary DNA synthesis.
Results
At baseline, mRNA for KLK3 was detected in 17 (89%, 95% CI 76–100%), PCA3 in 
10 (53%, 95% CI 30–75%), and TMPRSS2-ERG in 7 of 19 evaluable patients (37%, 
95% CI 15–59%). In contrast, the blood samples from all 32 healthy volunteers 
were reproducible negative for all markers. In response to docetaxel treatment, 
KLK3 levels decreased in 80% (95% CI 60–100%), PCA3 in 89% (95% CI 68–100%), 
and TMPRSS2-ERG in 86% (95% CI 60– 100%) of patients. 
Conclusions
The feasibility of a highly sensitive modified nucleic acid amplification assay to 
assess KLK3, PCA3, and TMPRSS2-ERG mRNA in the PBMC fraction from CRPC 
patients was demonstrated. Moreover, response of these markers to systemic 
treatment was shown.
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INTRODUCTION
Patients with advanced prostate cancer who undergo chemical or surgical castration 
will ultimately experience a relapse; this state is called castration-resistant 
prostate cancer (CRPC). The median overall survival (OS) of metastatic CRPC 
patients is 9–13 months.1 Treatment options for CRPC patients are limited. 
Cytotoxic chemotherapy, immunotherapy, second-line androgen deprivation 
therapy (the recently FDA approved abiraterone acetate), and novel androgen 
receptor signaling inhibitors (enzalutamide, ARN 509) are systemic approaches 
that have been found to prolong survival.2-7 However, these treatment modalities 
give only a modest prolongation of OS. 
The indication and sequence of administration for these new therapies becomes 
more important and the main issue in the management of CRPC therefore, is the 
lack of surrogate endpoints for treatment response and survival. Serum PSA, a 
serine protease secreted by prostate epithelial cells and also known as kallikrein-3 
(KLK3), is currently used as biomarker to measure disease burden and to predict 
treatment efficacy in CRPC patients.8-10 For docetaxel therapy, a ≥30% sPSA decline 
within 3 months of treatment initiation was determined to be the most optimal 
threshold for the association with overall survival.11 However, there is still a 
significant proportion of men for whom PSA response does not predict long-term 
benefit, and therefore, this threshold did not demonstrate consistent surrogacy 
for survival and cannot be used as a validated endpoint.12, 13 Post-therapy PSA 
changes are thus unlikely to become a Food and Drug Administration accepted 
surrogate endpoint for drug registration studies. Accordingly, there is a need to 
investigate new, reliable, and preferably non-invasive methods, which can be 
used as a reliable surrogate endpoint for survival.
In CRPC patients the enumeration of circulating tumor cells (CTCs) in the peripheral 
blood has been evaluated as a potential prognostic marker and predictor of overall 
survival.14-16 The CTC count,  defined as favorable (<5 CTCs) or unfavorable (≥5 
CTCs) at different time points before and after treatment with cytotoxic therapy 
was the strongest independent predictor of overall survival and would emphasize 
the CTC enumeration as a potential surrogate marker of therapy response and 
survival.14 
Molecular staging may provide more information about systemic disease activity 
and tumor load. A few studies already described a reverse-transcription (RT) 
polymerase chain reaction (PCR) to assess PSA mRNA expression in the peripheral 
blood mononuclear cell (PBMC) fraction.17, 18 Moreover, the last decades two 
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new prostate cancer specific biomarkers have been identified; Prostate Cancer 
gene 3 (PCA3) and the transmembrane protease, serine 2-ETS gene fusion 
(TMPRSS2-ERG).19, 20 Both markers have been studied intensively as diagnostic 
PCa markers.21, 22 Although, CTCs are supposed to be fundamental for the 
establishment of distant metastases, little is known about PCa specific markers in 
CRPC patients as a surrogate test for CTCs. Nevertheless, a recent study by Danila 
et al. described an analytic and clinical validation of a prostate cancer-enhanced 
mRNA detection assay in whole blood as a prognostic biomarker panel for 
survival. In this study, they identified a 5-gene panel, consisting of KLK3, KLK2, 
HOXB13, GRHL2, and FOXA1 and measured these markers in blood samples from 
97 metastatic CRPC patients with progressive disease.23 Results showed that 
expression of at least two of the five genes was a strong prognostic predictor for 
survival, comparable with the CellSearch system. Combining the gene panel and 
the CellSearch resulted in even enhanced power to discriminate between low- 
and high-risk patients relative to CellSearch alone.
In our study, we aimed to assess KLK3, PCA3 and TMPRSS2-ERG mRNA expression 
in the PBMC fraction of CRPC patients by using a highly sensitive modified 
reverse transcription-qPCR assay. In addition, we evaluated the response of these 
biomarkers to docetaxel chemotherapy treatment.
MATERIALS AND METHODS
Study design
In this prospective study, blood samples were obtained from 23 CRPC patients 
commencing docetaxel-based chemotherapy at the urology outpatient clinic 
of our university medical center. Three patients were excluded from biomarker 
analysis; one patient had an allergic reaction to docetaxel and immediately 
discontinued treatment after the first dose, one patient continued treatment in 
another hospital after three cycles and no follow-up data were available, and one 
patient deceased due to metastasized lung cancer during the study period. 
Approval for the study was obtained from the Institutional Review Board in 
accordance with all medical ethical requirements. After written informed consent 
was given, blood samples were obtained at four different time points; prior to 
the first chemotherapy course (baseline), prior to the fourth course (9 weeks), 
prior to the last (tenth) course (27 weeks), and 2 months after the last course (37 
weeks). As control groups, blood was drawn once from ten healthy age-matched 
men with no evidence of PCa, 10 men aged under 35 and 12 healthy women. 
Blood samples were collected into two 8ml cell preparation tubes (CPT) tubes 
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and processed within 2 hr. Clinical data (e.g., tumor stage, serum PSA levels, prior 
treatment, number of docetaxel regimens etc.) was extracted from the patients 
records.
Blood processing
Blood collection was coded and collected in two cell preparation tubes 
(Vacutainer1 CPTTM 8 ml). The blood processing reported below was according 
to manufacturer’s instructions. The tubes were centrifuged at room temperature 
for 20 min in a horizontal rotor at 1,800 relative centrifugal force (RCF) within 
2 hr of collection. The plasma layer and the cells from both CPT tubes were 
transferred to one conical centrifuge tube. Phosphate buffered saline (PBS) was 
added to a final volume of 14 ml, the tube was capped and the cells were mixed 
by inversion. Subsequently, the tubes were centrifuged for 15 min at 4°Celsius 
(°C) and 1500–1800 RCF. Supernatant was aspirated and 1ml PBS was added. The 
cell pellet was resuspended and the suspension was centrifuged at 4°C in a 1.5 
ml Safelock tube for 1 min at 1600 RCF. Supernatant was removed and cell pellets 
were immediately frozen in liquid nitrogen and stored at -80°C.
RNA extraction
The deep-frozen cell pellets were thawed on ice. Subsequently, RNA was extracted 
according to the TriPure reagent (Roche, Cat no. 11 667 165 001) guidelines. First 
1,000 ml TriPure Isolation Reagent was added to the cell pellet and cells were 
lysed by repetitive pipetting. Two hundred microliters chloroform was added to 
each sample. The tubes were shaken vigorously by hand for 15 sec and incubated 
at room temperature for 2–3min. Subsequently, they were centrifuged at 12,000 g 
for 15 min at 2–8°C to separate the solution into three phases. The aqueous upper 
layer, containing the RNA material, was transferred into a new tube. Isopropanol 
(500 µl) was added to precipitate the RNA. The samples were incubated at room 
temperature for 10 min. Again samples were centrifuged at 12,000 g for 10 min 
and the supernatant was discarded. The RNA pellet was washed in 1,000 ml 
75–80% ethanol, centrifuged at 7,500 g for 5 min and supernatant was discarded. 
The excess of ethanol was removed by air-draying and the RNA pellet was 
resuspended in RNase-free DEPC-treated water, incubated for 15 min at 55–60°C 
and stored at -80°C.
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Transcript amplification and reverse transcription
The Nanodrop 1000 (Thermo Scientific) was used for both quantification and 
purity checks of the RNA samples. First-strand cDNA syntheses were done using 
a modified Qiagen QuantiTect protocol. Ten micrograms RNA extracted from 
the mononuclear cells was dissolved in RNase-free water to a volume of 12 µl. 
Two microliters of cDNA wipeout buffer 7x, was added and incubated for 2 min 
at 42°C. Reversetranscription mastermix containing 1 µl Quantiscript Reverse 
Transcriptase, 4 µl Quantiscript RT buffer, and 1 µl Target-Specific Primers (3 µmol 
of each primer) was added. The primer sequences (TIB Molbiol) are displayed in 
Table 1. 
Table 1. Primer	pairs	and	hydrolysis	probe	sequences
Calibration curves with a wide linear dynamic range (10–1,000,000 copies) were 
generated using serial dilutions of linearized plasmids. Control samples with 
known template concentrations were used as a reference. Two microliters of 
each cDNA sample, representing approximately 460 µl blood, was amplified in 
a 20 µl PCR reaction, containing 10 µmol of each primer, 2 µmol of hydrolysis 
probe (TaqMan), and 1x Probe Master mix (Roche). The amplification conditions 
used were the following: 95°C for 10 min followed by 50 cycles at 95°C for 10 
sec, 60°C for 30 sec, and cooling at 40°C for 55 sec (LightCycler LC480, Roche). 
LightCycler 480 SW 1.5 software (Roche) was used for determining crossing 
point values. By extrapolation in the generated calibration curve, crossing point 
values of the samples were converted to concentrations. The assay performance 
of the real-time PCR experiments was evaluated during in-study validation. The 
amplification efficiency of the qPCR assays was determined using the calibration 
curves. The amplification efficiency was between min. 1.85 and max 2.05. The 
negative template controls were less than five copies. The reference control 
samples had an inter- and intra-assay variation <30%. Biomarker mRNA copies 
per milliliter from each patient are displayed in Table 2.
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Table 2.	Biom
arker	data	per	pati
ent	per	ti
m
epoint
sPSA
:	serum
	prostate	specific	anti
gen;	KLK3:	kallikrein-3;	PCA
3:	prostate	cancer	gene	3;	N
A
:	not	available.
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Statistical analysis
Since the study was of exploratory nature, statistics were mainly descriptive. 
RT-PCR was performed twice for each sample to test for reproducibility and 
biomarkers were classified positive if ≥20 copies per PCR reaction were present. 
The association between biomarker expression presence and survival outcome 
was assessed using the log rank test and a P-value <0.05 was considered statistically 
significant.
RESULTS
Peripheral blood samples from 20 CRPC patients commencing docetaxel treatment, 
collected at four different time points (i.e. baseline, 9 weeks, 27 weeks, and 37 
weeks) were analyzed. One baseline sample was not suitable for processing and 
one sample from the third time point was lost during transportation. Four patients 
discontinued treatment prematurely, were discharged from further follow-up 
at our hospital and were consequently not available for the fourth time point 
measurement. Therefore, 19 samples (95%) at baseline, 20 samples (100%) at 
the second time point, 19 samples (95%) at the third time point, and 16 samples 
(80%) at the last time point were available for biomarker evaluation.
The patient characteristics are presented in Table 3. The mean number of 
administered docetaxel regimens was 8 (range 2–10 cycles), 8 patients (40%) 
completed 10 cycles of docetaxel treatment and 12 patients (60%) discontinued 
at an earlier stage. The main reason for treatment discontinuation was serum PSA 
rise (58%).
Table 3.	Patient	characteristics
CRPC:	castration-resistant	prostate	cancer;	no.:	number;	 IQR:	 interquartile	range;	sPSA:	
serum	prostate	specific	antigen.
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Baseline biomarker expression
CRPC patient RT-PCR biomarker data, together with serum PSA levels, are 
displayed in Table 2. The median PSA level of the chemotherapy-naïve CRPC 
patients was 75.8 ng/ml KLK3 mRNA expression was detected in 17 of the 19 
evaluable CRPC patient samples at baseline (89%, 95% CI 76–100%), PCA3 
in 10 patients (53%, 95% CI 30–75%), and TMPRSS2-ERG in 7 patients (37%, 
95% CI 15–59%). Eleven patients (58%, 95% CI 36–80%) were either PCA3 or 
TMPRSS2-ERG positive and in 6 patients (32%, 95% CI 11–53%) both mRNAs were 
detected. The reproducibility for mRNA expression at baseline in a second RT-PCR 
was 100% for KLK3 and TMPRSS2-ERG and 84% for PCA3. This means that in all 
patients KLK3 and TMPRSS2-ERG expression in the first test, showed the same 
results in a second (validity) test of the same blood samples. For PCA3 16% of the 
test samples showed discrepancy in expression between the first and the second 
test. The median copy numbers per milliliter blood for positive KLK3 mRNA was 
208 (interquartile range [IQR] 60–2749), for positive PCA3 mRNA this was 117 
(IQR 55–290) and for positive TMPRSS2-ERG mRNA 19572 (IQR 11815–35206). 
In contrast, the blood samples from all 32 healthy volunteers were negative for 
KLK3, PCA3, and TMPRSS2-ERG mRNA (Table 4).
Table 4. Number	of	patients	(%)	with	positive	biomarker	expression	(≥	20	copies	per	PCR	
reaction)
CRPC:	castration-resistant	prostate	cancer;	KLK3:	kallikrein-3;	PCA3:	prostate	cancer	gene	
3;	T2-E:	TMPRSS2-ERG.
Biomarker expression and treatment response
Seven patients (35%) underwent all 10 docetaxel cycles and had evaluable samples 
at all four time points. The biomarker and serum PSA levels for this group at all 
time points are displayed as a bar graph in Figure 1.
Seventeen patients (85%) had evaluable samples at both baseline and after 9 
weeks of treatment and underwent at least four treatment cycles. Serum PSA 
levels decreased in 12 patients (71%, 95% CI 49–92%) and the median decrease in 
PSA was 51%. KLK3 decreased in 12 of 15 positive patients (80%, 95% CI 60–100%), 
PCA3 in 8 of 9 positive patients (89%, 95% CI 68–100%), and TMPRSS2-ERG in six 
of seven positive patients (86%, 95% CI 60–100%). Of the 12 patients that showed 
a decrease in KLK3 expression, 9 patients (75%, 95% CI 51–100%) also showed a
92
Figure 1. Expression levels for serum PSA (A), KLK3 (B), PCA3 (c) and TMPRSS2-ERG (D) at 
all time points in response to docetaxel treatment for seven CRPC patients who underwent 
ten treatment cycles (1=baseline, 2=9 weeks of treatment, 3=27 weeks of treatment, 4=2 
months after last cycle).
decrease in serum PSA level. From the other three patients, that showed an 
increase in PSA levels, two were PCA3 and TMPRSS2-ERG positive at baseline, and 
in accordance with KLK3, a decrease in expression level was detected at 9 weeks. 
Moreover, two of the three patients that had a KLK3 increase at 9 weeks also 
showed serum PSA increase at 9 weeks. 
In addition, at the last time point, most patients had increased serum PSA and 
biomarker expression levels compared to one of the previous measure points 
during treatment. Thirteen of 16 patients (81%, 95% CI 62–100%) had a serum 
PSA increase. Moreover, an increase was seen for KLK3 in 9 of 15 patients (60%, 
95% CI 35–85%), for PCA3 in 5 of 9 (56%, 95% CI 23–88%), and for TMPRSS2-ERG 
in 5 of 7 (71%, 95% CI 38–100%). The number of patients with positive biomarker 
expression at the different time points is presented in Table 4.
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Prognostic value of biomarker expression
To assess PCA3 and TMPRSS2-ERG as prognostic factors, survival information 
was used to calculate a correlation for baseline biomarker positive patients and 
baseline biomarker negative patients in relation to overall survival. The mean 
follow-up was 18.5 months (range from 10.7 to 33.1 months). Patients with 
negative baseline PCA3 expression had no statistically significant longer median 
survival (19.4 months [95% CI 13.9–24.8]) compared to patients with positive 
baseline PCA3 expression (15.0 months [95% CI 5.3–24.7], log rank P=0.907). 
Median survival for TMPRSS2-ERG negative (16.2 months [95% CI 10.1–22.3]) 
compared to the TMPRSS2-ERG positive patients (26.9 months [95% CI 15.7–38.2]) 
showed a clear trend towards a longer survival (P=0.175).
DISCUSSION
In the present study, we used highly sensitive modified reverse transcription-qPCR 
assays to detect prostate tissue specific KLK3 mRNA and prostate cancer specific 
PCA3 and TMPRSS2-ERG mRNAs in the PBMC fraction of a CRPC patient cohort 
and three control groups consisting of healthy volunteers. The use of gene-specific 
primers instead of random or mixed primers for the first-strand  complementary 
DNA (cDNA) synthesis reaction, resulted in a high analytical sensitivity of 
biomarker detection. KLK3 was detected in 89% (17 of 19) of CRPC patient 
samples at baseline. Since KLK3 mRNA is only produced by prostate cells, the 
detection in the PBMC fraction is indicative for circulating prostate cells.24 In turn, 
circulating prostate cells suggest a form of metastatic disease activity. However, 
earlier studies demonstrated the presence of KLK3 expression in peripheral blood 
samples from patients with clinically localized PCa (T1-2).17, 18 Accordingly, this 
suggests that in PCa, prostate cells are released into the bloodstream regardless 
of the disease stage, although in these studies expression was found to be higher 
in metastatic PCa patients. Our study did not include a group of localized PCa 
patients, nevertheless, the group of patients without PCa were negative for the 
biomarkers tested, indicating that KLK3 mRNA expression in the PBMC fraction is 
specific for PCa.
The rate of detectable KLK3 mRNA in this study is higher than described in earlier 
studies and might be explained by the use of gene-specific primers in the cDNA 
synthesis. These primers specifically prime the reverse-transcription activity 
to a specific target mRNA, instead of priming all mRNAs in the mixture, and 
thereby enhance analytical sensitivity. In a study by Ghossein et al. consisting of 
76 metastatic PCa patients, KLK3 was detected in only 34% and another study 
reported positive KLK3 mRNA expression in 14 of 18 metastatic patients (78%).17, 18 
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A more recent study included 180 patients with localized PCa, 76 metastatic CRPC 
patients, and 19 healthy volunteers. KLK3 mRNA was positive in 27 of 76 CRPC 
patients (36%) and in 15 of 180 patients (8%) with localized disease.25
Since KLK3 is a prostate tissue specific gene more than a cancer specific gene, the 
cancer specific markers PCA3 and TMPRSS2-ERG were also assayed. At baseline 
TMPRSS2-ERG was detected in 37% of the patients (7 of 19). This detection rate is 
in accordance with prior studies in which the fusion was detected in PCa specimen 
and urine from PCa patients.20, 26, 27 In a study by Danila et al., TMPRSS2-ERG 
expression in circulating tumor cells was assessed in 41 CRPC patients and an 
equal detection frequency of 37% was described.28
PCA3 mRNA was detected in 53% of CRPC patients. To date, only two studies 
have been performed analyzing PCA3 transcripts in blood samples from PCa 
patients. Jost et al. described an automated sample processing method, using an 
immunomagnetic fractionation procedure to enrich CTCs from peripheral blood 
specimens and subsequently performed molecular assays for KLK3, PCA3 and 
TMPRSS2-ERG. However, PCA3 was detected in only five of 33 patients (15%) and 
TMPRSS2-ERG in four of 33 patients (12%).29 In another study by Väänänen et al., 
mRNA levels were analyzed in peripheral blood samples from 67 PCa patients, 
including nine patients with metastatic PCa.30 Only two of these nine patients 
(22%) showed PCA3 mRNA above the limit of quantification. This low number of 
PCA3 positive patients can be explained by the use of random primers for cDNA 
synthesis. In contrast, the use of gene-specific primers together with increasing the 
template volume for the PCR reaction in our study enhanced biomarker analytical 
sensitivity and resulted in a higher fraction of PCA3 positive patients compared to 
assays using random primers (data	not	shown). To internally validate this method 
and assess test reproducibility, RT-PCR assays were performed twice on each 
sample. In total, three biomarker mRNAs were analyzed in 106 samples, that is, 
636 assays were carried out. In the second (validity) assay, biomarker expression 
was reproducible with respect to the first assay in 98%. Only 13 patient assays 
(2%) appeared not to be reproducible (data	not	shown). This data demonstrate 
the high reliability of the assays.
Although, this was an exploratory study, and thus the patient group was too small 
to make a valid statement on the prognostic value of these biomarker expression 
status, the biomarkers were measured longitudinally during treatment to assess 
a biomarker treatment response. In most patients with positive biomarker 
expression at baseline a decrease in biomarker expression was detected after 
three cycles of docetaxel treatment (80–89%). Serum PSA levels decreased in 71% 
of patients as response to three cycles of docetaxel; however, a 75% conformity 
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between KLK3 expression and serum PSA response was detected. Furthermore, at 
the last measure point biomarker expression increased in most patients (56–71%), 
suggesting a reflection of an increasing disease burden after discontinuation of 
the treatment. Although this study was not designed to evaluate the prognostic 
value of these markers, results imply that these biomarkers may be used as a 
prognostic tool in CRPC patients and/or to measure therapy effect; however, 
validation studies on this endpoint are ongoing.
CONCLUSIONS
To our knowledge this was the first study that combined detection of KLK3, PCA3 
and TMPRSS2-ERG expression assays in the PBMC fraction from CRPC patients 
and additionally assessed expression levels over time in relation to systemic 
treatment. The results demonstrate the feasibility of a highly sensitive reverse 
transcription-qPCR assay, using gene-specific primers in the cDNA synthesis, 
as a nucleic acid test to detect biomarkers in the PBMC fraction. Since no valid 
prognostic value could be demonstrated for the concerning biomarkers, larger 
prospective clinical studies need to shed more light on the relevance of these 
findings.
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PROSTATE CANCER RISK FACTORS AND DIAGNOSIS
Prostate cancer is a major health problem worldwide with annually over 300.000 
men dying from this disease.1 The incidence is highest in the Western population 
with a lifetime risk of approximately one in six. African Americans have the highest 
risk of developing prostate cancer during lifetime and Asians are less commonly 
affected. Age is attributed as the major risk factor for developing prostate cancer 
and the risk rapidly rises after the age of 40 years. A twofold increased risk of 
prostate cancer is seen in men with one or two affected first-degree relatives 
and a large Scandinavian study estimated that approximately 42% of the risk 
of prostate cancer could be explained by heritable factors.2, 3 To date numerous 
other risk factors (diet, smoking, hormone levels, etcetera) for prostate cancer 
have been studied, however, the most promising risk stratification for prostate 
cancer may be achieved by identifying genetic polymorphisms and combine these 
with the above mentioned clinical risk factors. This hypothesis was tested in a 
large population-based study, including over 47.000 men without prostate cancer 
between 50-69 years of age. This study examined the role of plasma protein 
biomarkers, genetic single nucleotide polymorphisms and clinical variables as 
a predictor for diagnosis of high-grade prostate cancer. They concluded that by 
combining these factors the number of prostate biopsies and the detection of 
clinically insignificant disease can be reduced, while maintaining the sensitivity to 
clinically significant prostate cancer.4
Patterns and trends in prostate cancer incidence have been influenced by PSA 
screening in asymptomatic men and a tremendous increase in incidence was 
observed after the introduction and the widespread use of PSA testing. However, 
the controversy of PSA testing led to the recommendation against PSA screening 
and this subsequently resulted in a declining prostate cancer incidence in the last 
years.5 Likely as a result of the strong decline in random PSA testing, a recent 
study showed that the number of men with advanced prostate cancer at diagnosis 
has been rising significantly in the last years. Therefore, despite the drawbacks of 
PSA testing, these results strongly suggest that PSA based screening should be 
improved and not totally abandoned.6 
In an attempt to improve risk stratification for the individual patient, several 
clinical risk factor based calculators have been developed and validated. Two 
well known calculators that are online available are the PCPT risk calculator 2.0 
and the ERSPC risk calculator.7, 8 The clinical factors implemented in the first risk 
calculator are PSA, age, digital rectal examination, family history of prostate 
cancer, race and prior prostate biopsies.7 The latter includes PSA, age, digital rectal 
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examination, family history of prostate cancer, prostate volume and prior prostate 
biopsies.8 These risk calculators provide a better predictive accuracy compared 
to PSA alone and can guide in decision making. However, still a considerable 
number of patients is burdened with the fact of overdiagnosis and overtreatment. 
Translational research has led to several new commercially available urine-, blood- 
and tissue-based markers. These novel molecular markers can make a significant 
improvement on predictive accuracy for clinically significant prostate cancer 
and therewith reduce the number of unnecessary biopsies and overtreatment. 
However, since no molecular marker alone can reach sufficient power for reliable 
estimation of prostate cancer prognosis, the combination of multiple markers 
with clinical risk factors is needed to distinguish between clinically insignificant 
and significant prostate cancers.   
URINE AS A BIOMARKER SUBSTRATE FOR THE PREDICTION OF PROSTATE CANCER
Urine can be obtained non-invasively and due to the anatomical localisation of 
the prostate in relation to the urethra, urine could therefore serve as a valuable 
substrate for prostate cancer biomarker measurement. The value of a digital 
rectal examination (DRE) has been demonstrated, showing increased biomarker 
expression in the first-catch urine after performing a DRE.9, 10 
The current commercially available urine tests for prostate cancer use whole urine 
as a substrate, despite some of the pre-validation studies have been performed 
on urinary sediments.11-13 The preference for using whole urine over sediments 
in these tests is based on the ease of standardization of pre-analytical sample 
handling. Centrifugation followed by filtration yields besides sediments also a 
fraction containing exosomes. We studied this fraction as a separated fraction in 
urine, with the hypothesis that the molecular information within these vesicles 
is better protected compared to whole cells and may have different diagnostic 
information. If mRNA is better preserved and analytical sensitivity is higher, a 
DRE might be saved, making the urine more ideal as a substrate for widespread 
screening. Unfortunately, we were not able to demonstrate this higher analytical 
sensitivity of biomarker expression in exosomes.14 Even more, in a second study 
we demonstrated that analytical sensitivity was highest in whole urine samples 
with a DRE increasing the biomarker informative rate.15 This finding corroborates 
the recommendation to the use of whole urine after DRE in a routine clinical 
urine test. Nonetheless, a recent study described the feasibility of a purification 
technique to routinely isolate exosomal RNA from first-catch, non-DRE urine 
that can be used to derive the molecular signatures of PCA3 and ERG that are, 
in combination with clinical risk factors, predictive of the diagnosis of high-grade 
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prostate cancer.16 These findings have not yet been validated in other studies, 
however, results seem promising. Large future studies will need to clarify the true 
value of exosomes as a substrate for prostate cancer biomarker measurement by 
a direct diagnostic and prognostic comparison between whole urine and exosome 
biomarker outcome. So far, whole urine seems to be the preferred substrate 
fraction for clinical RNA biomarker measurement. 
QUALITY OF BIOMARKER STUDIES
The current “gold” standard for prostate cancer diagnosis is biopsy-based 
histopathology, obtained through a systematic procedure taking random 
transrectal ultrasound guided biopsies. Herein lies a pitfall for prostate cancer 
biomarker related studies. Since the nature of the procedure is random, there is 
a substantial risk of missing prostate cancer (a false-negative result); estimated at 
approximately 10-22%.17 Moreover, the Gleason score grading has a high inter- 
and intrapathologist variability which can result in undergrading of low-grade 
tumours.18, 19 Both these biopsy related factors might be a limitation in biomarker 
studies, since these non-detected or undergraded cancers contribute to the 
reduction in test sensitivity. 
To warrant the scientific quality of translational biomarker studies, various criteria 
and guidelines have been designed to permit an accurate description of analytical 
validity and clinical utility for biomarker implementation. A recent update from 
the 2003 Standards for Reporting Diagnostic Accuracy (STARD) statement lists 
30 essential items to improve completeness and transparency in reporting 
of diagnostic accuracy studies.20 Another checklist to objectively assess the 
appropriateness and quality of study designs, methods, analyses and improve the 
ability to compare across prognostic biomarker studies, arose from the Reporting 
Recommendations for Tumor Marker Prognostic Studies (REMARK) guideline.21 
A third aid tool, the Biospecimen Reporting for Improved Study Quality (BRISQ) 
guidelines, was designed to provide a standardized report of pre-analytical 
information on biospecimen in order to improve the quality of research utilizing 
human tissues.22
These guidelines are essential for the understanding and transparency of 
biomarker studies, making it easier to assess study quality, potential biases 
and the relevance in clinical practice. In my opinion, future biomarker studies 
therefore need to report according to these guidelines to improve the quality of 
these studies and retain transparency in the process of biomarker development 
and validation.   
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NOVEL DIAGNOSTIC AND PROGNOSTIC PROSTATE CANCER BIOMARKERS
Recently, various prostate cancer associated diagnostic markers have been 
identified and demonstrated their additive value in combination with clinical risk 
factors, e.g. PCA3, PCA3+TMPRSS2-ERG and the 4-kallikrein panel.18, 23, 24 The two 
currently commercially available blood-based tests that demonstrated improved 
accuracy in high-grade prostate cancer diagnosis, relative to PSA, are the prostate 
health index (phi) and the 4K score.23, 25 A head-to-head comparison between 
phi and the 4K score showed a similarly improved discrimination predicting 
high-grade prostate cancer.26
The new urinary HOXC6-DLX1 biomarker panel described in this thesis, has shown 
to be a promising prognostic panel, combining it with clinical risk factors.27 An 
improved accuracy in the identification of men with high-grade prostate cancer was 
seen in a direct comparison to PCA3 and the PCPTRC 2.0 alone. These promising 
results have led to the commercialization of this risk score into the SelectMDx 
test. Analyses in a cost-effectiveness study, using the accuracy data of this new 
urinary biomarker-based risk score, demonstrated a reduction in healthcare costs 
and improvement in quality of life. And although these results are promising, 
this risk score will need additional clinical validation in further prospective trials. 
Future studies need to be performed to compare the currently available urine- 
and blood-based markers in a head-to-head comparison together with mpMRI 
(biopsy) outcome and, where feasible, with prostatectomy histopathology as a 
reference. Other variables that need to be studied are the biological variability 
of the score and the value of longitudinal risk score assessment, for instance in 
active surveillance cohorts. 
PREDICTIVE AND SURROGATE ENDPOINT MARKERS FOR CASTRATION-RESISTANT 
PROSTATE CANCER
The therapeutic options in the field of castration-resistant prostate cancer (CRPC) 
are rapidly evolving and various new systemic agents have been approved for 
the treatment of CRPC patients. These agents have been subjected to extensive 
assessment in clinical trials and include cytotoxic chemotherapy (docetaxel, 
cabazitaxel), immunotherapy (sipuleucel-T), androgen receptor signaling 
inhibitors (abiraterone, enzalutamide) and radioisotope therapy (radium-223).28-34 
In addition, there are even more novel agents currently in development.35, 36 With 
all these new therapies, finding the optimal therapeutic sequence to maximize the 
clinical benefit is a major challenge. However, the main issue in the development 
of new therapies for CRPC patients and the sequencing of these new agents, is the 
lack of predictive and surrogate endpoints for therapy response and survival. PSA 
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value changes in addition to imaging, according to the RECIST criteria and PCWG2 
guidelines, are often used as a measure of treatment response.37, 38 However, 
the value of PSA changes in CRPC treatment may depend on the administered 
agent and the time of sampling, and therefore PSA may not be a favourable 
surrogate marker for disease progression or survival.39, 40 Consequently, there is 
a need for novel, reliable and preferably non-invasive predictive and surrogate 
markers to guide in clinical decision making in CRPC patients and to accelerate the 
development process of novel treatments. 
The enumeration of circulating tumor cells (CTCs) in blood is currently the only 
Food and Drug Administration approved method demonstrated to be a surrogate 
for overall survival in various solid tumours, including prostate cancer.41-43 More 
profound profiling of the CTCs with tumour specific biomarkers might contribute 
to the identification of patients that would benefit from treatment. In our study 
we demonstrated the feasibility to detect the prostate (cancer) specific markers 
KLK3, PCA3 and TMPRSS2-ERG in the peripheral blood mononuclear cells of CRPC 
patients, prior to and during docetaxel treatment. Another study, originating 
from the rationale that resistance to androgen receptor signaling inhibitors may 
be caused by the presence of androgen receptor splice variants, Antonarakis et 
al. assessed androgen receptor splice variant 7 messenger RNA (AR-V7) in CTCs 
from patients receiving enzalutamide or abiraterone. The presence of AR-V7 was 
negatively associated with PSA progression-free survival, clinical or radiographic 
progression-free survival and overall survival and might therefore be a potential 
predictive marker.44 Moreover, it was demonstrated that AR-V7 was not associated 
with primary resistance to taxane chemotherapy.45
Large phase III CRPC treatment studies should implement the assessment of 
prostate cancer specific markers as potential predictive and surrogate endpoints. 
This might strengthen current literature and might also lead to the discovery of 
novel markers that may serve as a treatment selection biomarker in CRPC.
PREDICTIVE AND THERAPEUTIC TARGET MARKERS
The rationale for most drug development in metastatic prostate cancer has been 
focused on the androgen receptor. However, practically all patients with metastatic 
prostate cancer will eventually develop resistance and disease progression 
despite currently available treatment options. In the next step towards improving 
advanced prostate cancer therapy, there might be a potential role for prostate 
cancer specific biomarkers as therapeutic targets. The most recent finding herein 
is the presence of AR-V7, as explained earlier.44 The aim of targeted therapy is 
to avoid the ‘one-size-fits-all’ treatment approach and to effectuate a more 
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individualized approach according to molecular stratification of the patient. 
The most well-known example of targeted therapy in oncology is treatment with 
trastuzumab (Herceptin®) in breast cancer, a therapy directed against cancers 
that overexpress the human epidermal growth factor receptor 2 protein (HER2) 
in a particular subgroup of patients.46 Another example is alteration of the cell 
growth signaling protein BRAF-V600E in patients with melanoma, which resulted 
in vemurafenib (Zelboraf®) that targets this mutant form of BRAF.47 
The use of a targeted therapy should be restricted to patients whose tumour 
has a specific mutation that codes for the target. A major future challenge for 
biomarker research and drug development technology is to identify patients’ 
tumour characteristics that can be used as a target for therapy and select patients 
that would benefit from this therapy. The basis for this has been set through the 
establishment of a multi-institutional clinical sequencing infrastructure to conduct 
prospective whole-exome and transcriptome sequencing of bone or soft tissue 
biopsies from metastatic prostate cancer patients, in a study by Robinson et al.48
PROSPECTS IN PROSTATE CANCER BIOMARKER RESEARCH
Prostate cancer is, as most cancer types, a heterogeneous disease. The current 
limitation in diagnosis, based on PSA testing, is the lack of specificity for the 
detection of prostate cancer. For the discovery and development of new prostate 
cancer biomarkers, understanding of cancer genetics and cancer biology is 
essential. Moreover, the optimal benefit for individualized risk stratification can 
be made by combining genetic factors with clinical risk factors. 
The urinary HOXC6-DLX1 biomarker-based risk score provides a promising test to 
identify patients at risk for high-grade prostate cancer. Analysis for implementation 
of the test even implied to effectuate a gain in quality of life for men with PSA 
levels >3 ng/ml and a benefit in health care costs. A major challenge, however, 
will be the widespread implementation of this risk score in clinical practice, since 
clinicians often continue to rely on the more conventional diagnostic pathway. 
Nevertheless, more clinical validation studies should strengthen the scientific 
proof for widespread use by urologists. Therefore, future studies of this risk score, 
incorporating MRI-guided (fusion) biopsy outcome as an endpoint are important. 
The subsequent step should then be to assess the value of this biomarker-based 
risk score in men on active surveillance. In this population the risk score might be 
a valuable tool to better stratify the men at risk of harbouring high-grade prostate 
cancer and therefore stratify patients for (MRI-guided) biopsies. Furthermore, 
in the future this risk score might be beneficial for use in first-line medicine as 
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a screening tool. For this purpose large prospective population based studies 
need to be designed in accordance with the methods used in previous screening 
studies.
The purpose of implementing novel prostate cancer biomarkers in clinical practice 
is to tailor medical decisions to the individual characteristics of each patient; 
personalized or precision medicine. In the diagnostic process this contributes to 
the reduction in overdiagnosis and overtreatment. In CRPC patients, biomarkers 
might predict which patients will benefit from a certain treatment and thereby 
as well a reduction in overtreatment can be gained. The exploratory study in this 
thesis, demonstrating the feasibility to detect KLK3, PCA3 and TMPRSS2-ERG in 
the peripheral mononuclear cells of CRPC patients, is a first step in the detection of 
prostate cancer specific biomarkers in this group of patients. Although progress is 
being made in this field, especially in profiling CTCs, larger, multicenter studies are 
needed. This can be achieved by incorporating biomarker endpoints in the many 
phase I, II and III pharmacological studies for CRPC. In this way biomarkers can be 
evaluated from the moment that a new therapy is being introduced, which can 
yield interesting results and might save time and money in biomarker discovery.
Moreover, most valuable information on tumour biology in CRPC patients can 
be gained from metastatic pathology. Thus, future predictive and surrogate 
biomarker studies need to be designed with obtaining metastatic tissue samples. 
Although this procedure is invasive and uncommon practice in CRPC patients, 
molecular genetic characterization of bone and soft tissue metastasis can be 
valuable in the understanding of tumour biology and will be of great importance 
for the identification of novel predictive and surrogate biomarkers. 
The transition from a potential biomarker candidate to a clinically-used test is a 
time-consuming process, which has been shown in the development of biomarkers 
for other tumor types (e.g. breast, cervix and colon cancer). During this process 
various phases of development need to be conducted to reach clinical validity.
In prostate cancer, future studies on the currently promising urine- and 
blood-based biomarkers need to be focused on further clinical validation in large 
populations, ideally in a head-to-head comparison within the same group of 
patients. Access to large sample numbers can be gained by the incorporation of 
biomarkers in well-designed multi-institutional clinical studies. Once a biomarker 
(panel) has proven sufficient value as a diagnostic or prognostic test, prospective 
evaluation in a screening setting can be performed. During this process it is very 
important that studies are designed according to earlier discussed guidelines to 
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improve quality, reproducibility and transparency. Also it is of great importance to 
invest in statistically powered studies at an early stage of biomarker research to 
avoid wasted efforts in continuing to evaluate a non-predictive biomarker. 
Ultimately, significant progress in the field of biomarker research can only 
be achieved through good quality research and optimal collaboration in a 
multidisciplinary team of clinicians, laboratory technicians and pharmacists from 
multiple institutions.
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SUMMARY
Prostate cancer is the most commonly diagnosed cancer in men in the Western 
society and in the Netherlands approximately 10.000 men are annually diagnosed 
with this disease. A tremendous increase in incidence was observed due to the 
introduction and the widespread use of serum prostate specific antigen (PSA) 
testing. Despite prostate cancer can be diagnosed in an earlier stage due to PSA 
testing, PSA lacks specificity for prostate cancer, resulting in the overdiagnosis of 
clinically insignificant prostate cancers. To overcome this flaw, extensive research 
in the field of prostate cancer detection has been performed and novel biomarkers 
have been discovered. 
A detailed overview of the current developments in prostate cancer biomarkers 
and the recent establishment of novel biomarkers is described in chapter 2. The 
biomarkers that are discussed in this chapter are subdivided, based on three 
human substrates for biomarker measurement; urine, blood and tissue. 
Urine is a substrate that can be obtained in a noninvasive manner. And due to 
the anatomical localization of the prostate in relation to the urethra, first-voided 
urine contains prostatic cells that represent biochemical processes within this 
gland. Subsequently, by performing a digital rectal examination, prostatic cells are 
mobilized towards the urethra and biomarker expression in the first-catch urine is 
increased. In chapter 3 the value of a digital rectal examination on KLK3, PCA3 and 
TMPRSS2-ERG expression levels was evaluated for two urinary fractions; cell pellet 
and exosomes. In a prospective study, including 30 patients undergoing prostate 
biopsies, urine samples were collected before and after digital rectal examination 
and KLK3, PCA3 and TMPRSS2-ERG mRNA expression levels were measured in the 
cell pellet and exosomes. The results showed that 10% of the cell pellet samples 
contained precipitation of impurities, for which no mRNA could be extracted. 
In comparison, none of the exosome samples contained precipitation. With 
these results it seemed that exosomes are a more robust source for biomarker 
measurement in urine compared to cell pellets. However, analytical sensitivity, 
defined as a detection limit in copies per ml, was lower in exosomes. This means 
that the RNA yield in exosomes is lower compared to cell pellet. Nonetheless, 
performing a digital rectal examination resulted in higher biomarker expression 
levels in both first-catch urinary fractions. 
The major challenge in prostate cancer diagnosis is to improve the detection 
of clinically significant prostate cancer in an early stage of disease. Moreover, 
prostate cancer overdiagnosis and overtreatment can be reduced if prostate 
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cancer specific biomarkers could accurately distinguish indolent from aggressive 
disease. In chapter 4 we described the detection and validation of a urinary 
molecular biomarker-based risk score to detect high-grade (Gleason score ≥7) 
prostate cancer upon biopsy in two prospective multicenter studies. Urine was 
collected for mRNA measurement after digital rectal examination and prior to 
prostate biopsy from a first cohort consisting of 519 men and a second cohort 
consisting of 386 men. The selection of the most informative biomarkers was 
based on an earlier identification and selection study and resulted in the strongest 
clinical performance for the combination of HOXC6 and DLX1 with an area under 
the curve (AUC) of 0.76 for the detection of high-grade prostate cancer in the 
training cohort. This combination was successfully validated in the second cohort 
(AUC of 0.73; p = 0.4). The addition of other markers to this model did not result 
in further performance improvement. The combination of these two biomarkers 
with traditional risk factors (age, PSA, PSA density, digital rectal examination, 
family history of prostate cancer and prior prostate biopsy) in a logistic regression 
model, resulted in a predictive accuracy of 0.86 (95% confidence interval [CI] 
0.80-0.92) for high-grade prostate cancer in the validation cohort. Another model, 
excluding diagnostic digital rectal examination results, to avoid variables subject 
to interobserver variability, obtained an AUC of 0.90 (95% CI 0.85-0.95). Both 
models did not demonstrate a significant change in predictive accuracy between 
the training and validation cohort. An evaluation of clinical utility using decision 
curve analysis indicated a strong net benefit to identify men with high-grade 
disease and the best reduction in the number of unnecessary biopsies compared 
to the PCPT risk calculator and the PCA3 assay alone. 
In addition to this study and in the current light of growing health care costs, in 
chapter 5 we assessed the cost-effectiveness and quality of life effects using this 
novel urinary biomarker-based risk score in comparison with the current standard 
of care in men with PSA levels >3 ng/ml. The diagnostic pathway including the 
biomarker-based risk score with a cut-off accompanying a sensitivity of 95.7% for 
high-grade prostate cancer resulted in a net gain of €128 and 0.025 quality-adjusted 
life years (QALYs) per patient compared to the standard of care strategy, using 
only PSA to select patients for transrectal ultrasound-guided prostate biopsy. 
The highest gain in QALYs and costs was achieved by reducing the diagnosis of 
low-grade prostate cancers, and the subsequent reduction of treatment or 
follow-up with active surveillance. The sensitivity analyses demonstrated that the 
disutility assigned to active surveillance had a high impact on the QALYs gained. In 
this study, the expected loss in QALYs due to a minor chance of missing high-grade 
prostate cancer was outweighed by the expected health gain, which was mainly 
caused by reducing the number of low-grade prostate cancer diagnoses and to a 
lesser extent by the reduction in prostate biopsies.
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Eventually, practically all patients with advanced prostate cancer who have 
undergone chemical or surgical castration will progress to a castration-resistant 
prostate cancer (CRPC) state. Despite the therapeutic options in this field are 
rapidly evolving, the main issue in the management of CRPC patients and the 
development of new therapies is the lack of predictive and surrogate endpoints for 
therapy response and survival. Circulating tumor cells, derived from the peripheral 
blood, are currently the only approved surrogate endpoint for overall survival and 
so far little is known about more profound prostate cancer specific biomarker 
profiling of blood specimen. Chapter 6 demonstrates the results of a feasibility 
study of a highly sensitive modified nucleic acid amplification assay to assess 
KLK3, PCA3 and TMPRSS2-ERG mRNA in the peripheral blood mononuclear cell 
fraction from CRPC patients. Blood samples from 20 CRPC patients on docetaxel 
treatment were analyzed at four different time points; prior to treatment, at 9 
weeks, 27 weeks and 2 months after treatment. Ten age-matched men, 10 men 
under 35 years of age and 12 women were used as control group from which blood 
was drawn once. Results showed that at baseline KLK3 expression was detected 
in 17 (89%, 95% CI 76-100), PCA3 in 10 (53%, 95% CI 30-75) and TMPRSS2-ERG in 
7 (37%, 95% CI 15-59) of 19 evaluable patients. In contrast, the blood samples of 
all 32 healthy controls were reproducible negative for these markers. In response 
to docetaxel treatment, KLK3 levels decreased in 80% (95% CI 60-100), PCA3 in 
89% (95% CI 68-100) and TMPRSS2-ERG in 86% (95% CI 60-100) of patients. With 
this study the feasibility of a highly sensitive modified nucleic acid amplification 
assay to assess KLK3, PCA3 and TMPRSS2-ERG mRNA in the peripheral blood 
mononuclear cell fraction from CRPC patients has been demonstrated. Moreover, 
response of these markers to systemic treatment was shown. 
In summary, this thesis demonstrates the clinical application of various urine- 
and blood-based prostate cancer biomarkers. The necessity of a digital rectal 
examination prior to prostate cancer urinary biomarker analysis has been shown. 
Subsequently, a urinary molecular biomarker-based risk stratification tool for 
high-grade prostate cancer which can aid in biopsy decision making has been 
described with the suggestion that implementation of this novel risk score can 
improve the quality of life of men suspected for prostate cancer and reduce 
healthcare costs. Furthermore, demonstrating that prostate (cancer) specific 
biomarkers can be measured in the blood of CRPC patients might be an important 
step in the ongoing search for a predictive and surrogate endpoint marker.
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Prostaatkanker is de meest voorkomende kanker in mannen in de westerse wereld 
met een incidentie van ongeveer 10.000 nieuwe patiënten per jaar in Nederland. 
De incidentie is sinds eind vorige eeuw enorm toegenomen, wat grotendeels te 
wijten is aan het gebruik van prostaat specifiek antigeen (PSA) voor het opsporen 
van prostaatkanker in de dagelijkse praktijk. Hoewel prostaatkanker in een 
vroeger stadium kan worden gediagnosticeerd door het gebruik van PSA, leidt de 
lage specificiteit tot overdiagnostiek. Met het oog op deze tekortkoming vindt er 
veel onderzoek plaats op het gebied van prostaatkanker biomarkers, wat heeft 
geresulteerd in de ontdekking en implementatie van nieuwe biomarkers voor de 
diagnostiek van prostaatkanker.
Een gedetailleerde beschrijving van de ontwikkelingen en totstandkoming van de 
huidige prostaatkanker biomarkers is opgenomen in hoofdstuk 2. De biomarkers 
die in dit hoofdstuk worden beschreven zijn onderverdeeld in de drie meest 
toegepaste substraten voor het bepalen van biomarkers, namelijk urine, bloed 
en weefsel.
Urine is een biomarker substraat dat op een niet-invasieve manier kan worden 
verkregen. De hypothese dat de eerst geloosde urine prostaatcellen bevat die 
representatief zijn voor de biochemische processen in de prostaat, is gebaseerd 
op de anatomische ligging van de prostaat ten opzichte van de urethra. Gedacht 
wordt dat door middel van het uitvoeren van een rectaal toucher prostaatcellen 
naar de urethra worden gemobiliseerd, wat resulteert in een verhoogde 
biomarker expressie in de urine. In hoofdstuk 3 wordt de waarde van dit rectaal 
toucher op de expressie waarden van KLK3, PCA3 en TMPRSS2-ERG in twee 
separate urinefracties beschreven; het urine sediment (cel fractie) en exosomen. 
In deze prospectieve studie werden 30 patiënten geïncludeerd, waarbij vóór en 
na rectaal toucher urine werd afgenomen voorafgaand aan het ondergaan van 
prostaatbiopten. De biomarker expressie waarden (mRNA) van KLK3, PCA3 en 
TMPRSS2-ERG werden gemeten in zowel de cel fractie als in de exosomen fractie. 
In 10% van de cel fracties kon geen mRNA worden bepaald ten gevolge van 
neerslag in de samples (precipitatie), in tegenstelling tot de exosomen fractie, 
waarvan elk sample analyseerbaar was. Met dit resultaat lijkt het dat exosomen 
een robuuster substraat vormen ten opzichte van urine sediment. Echter, de 
kwantitatieve mRNA opbrengst van de biomarkers, het analytisch vermogen, 
was lager in de exosomen fractie. Daarnaast werd in deze studie aangetoond dat 
het verrichten van een rectaal toucher resulteert in hogere biomarker expressie 
waarden in zowel urine sediment als exosomen.
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Om overdiagnostiek en overbehandeling te verminderen, is er behoefte aan 
een test die mannen met klinisch significant prostaatkanker nauwkeurig kan 
identificeren. Hoofdstuk 4 beschrijft de detectie en validatie van een risico 
model voor het identificeren van hooggradig prostaatkanker (Gleason score ≥7) 
middels een biomarker panel in urine. In twee prospectieve, multicenter studies 
(cohort 1: n=519; cohort 2: n=386) werd urine verzameld voorafgaand aan het 
nemen van prostaatbiopten. De resultaten van cohort 1 werden gebruikt voor 
het ontwikkelen van het model en gevalideerd in het onafhankelijke cohort 
2. De hoogste area under the curve (AUC) voor de detectie van hooggradig 
prostaatkanker werd gezien voor de combinatie van HOXC6 en DLX1 en was niet 
verschillend tussen beide cohorten (cohort 1: 0.76 en cohort 2: 0.73, p = 0.4). De 
toevoeging van andere markers resulteerde niet in een significant toegevoegde 
waarde. De combinatie van deze biomarkers met klinische risicofactoren (leeftijd, 
PSA, PSA dichtheid, rectaal toucher, familie geschiedenis voor prostaatkanker en 
voorgaande prostaat biopten) in een logistisch regressie model, resulteerde in 
een AUC van 0.86 (95% betrouwbaarheidsinterval [BI] 0.80-0.92) voor de detectie 
van hooggradig prostaatkanker in het validatie cohort. Een tweede model, 
waarbij de bevindingen van het rectaal toucher werden uitgesloten om in het 
model alleen objectieve variabelen te betrekken, had een AUC van 0.90 (95% 
BI 0.85-0.95). Beide modellen lieten ten opzichte van elkaar geen significante 
verschillen in uitkomst zien. Decision curve analyse liet zien dat gebruik van deze 
risico score een hogere reductie in het aantal onnodige biopsieën bewerkstelligt, 
in vergelijking met de PCPT risico calculator en de PCA3 test alleen. 
In aanvulling op deze studie en met oog op de stijgende kosten in de 
gezondheidszorg, is in hoofdstuk 5 een kosteneffectiviteitsanalyse beschreven, 
waarin het gebruik van de nieuwe risico score op basis van een moleculaire 
urinetest wordt vergeleken met het huidige diagnostische traject bij mannen 
met PSA waarden >3 ng/ml. Het gebruik van de nieuwe risico score om mannen 
te selecteren voor prostaatbiopten resulteerde in een netto winst van €128,- en 
0.025 quality-adjusted life years (QALYs) per patiënt ten opzichte van het huidige 
diagnostische traject. Hierbij werd een grenswaarde van de risico score in acht 
genomen met een sensitiviteit van 95.7% voor hooggradig prostaatkanker. De 
meeste winst in QALYs en kosten werd bewerkstelligd door de reductie van het 
aantal laaggradig prostaatkanker diagnoses en de reductie van de daaropvolgende 
behandeling en follow-up. De sensitiviteitanalyses toonden dat de utiliteit die 
werd toegewezen aan active surveillance een grote impact had op het aantal 
gewonnen QALYs. Het verlies aan QALYs veroorzaakt door de kans om hooggradig 
prostaatkanker te missen werd gecompenseerd door de gezondheidswinst, 
welke met name werd behaald door het voorkomen van de diagnose laaggradig 
prostaatkanker en in mindere mate door de reductie van het aantal biopsieën.
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Theoretisch gezien zullen alle patiënten met vergevorderd prostaatkanker die 
medicamenteuze of chirurgische castratie hebben ondergaan een castratie-
resistent prostaatkanker (CRPC) stadium ontwikkelen. Hoewel de therapeutische 
opties voor deze groep patiënten zich snel ontwikkelen, is het voornaamste 
gebrek bij de behandeling van CRPC patiënten en de ontwikkeling van nieuwe 
therapieën voor deze groep patiënten, het ontbreken van een betrouwbare 
marker voor respons op behandeling en overleving. Circulerende tumorcellen 
in het bloed zijn momenteel de meest betrouwbare surrogaat eindpunt markers 
voor overleving. Verder is er nog weinig bekend over prostaat(kanker) specifieke 
biomarkers in CRPC patiënten. Hoofdstuk 6 laat de resultaten zien van een 
exploratieve studie naar de mogelijkheid van een nieuw ontwikkelde assay om 
KLK3, PCA3 en TMPRSS2-ERG mRNA te meten in het bloed van CRPC patiënten. 
Van 20 CRPC patiënten werden op vier verschillende momenten gedurende 
docetaxel chemotherapie behandeling bloedmonsters afgenomen (voor start van 
de behandeling, tijdens week 9, tijdens week 27 en 2 maanden na de behandeling). 
Als controlegroep werd eenmalig bloed afgenomen van 32 gezonde vrijwilligers 
(10 mannen in dezelfde leeftijdscategorie, 10 mannen <35 jaar en 12 vrouwen). 
Alle bloedmonsters werden geanalyseerd op KLK3, PCA3 en TMPRSS2-ERG mRNA 
middels een kwantitatieve nucleïnezuur amplificatie assay met gen-specifieke 
primers. Resultaten lieten zien dat mRNA KLK3 werd gedetecteerd in 17 (89%, 
95% BI 76-100), PCA3 in 10 (53%, 95% BI 30-75) en TMPRSS2-ERG in 7 (37%, 95% 
BI 15-69) van de 19 evalueerbare chemotherapie-naïeve patiënten. De samples 
van de controle groepen waren bij herhaling negatief voor alle markers. Tijdens 
docetaxel behandeling daalden KLK3 waarden in 80% (95% BI 60-100), PCA3 in 
89% (95% BI 68-100) en TMPRSS2-ERG in 86% (95% BI 60-100) van de patiënten. 
Deze studie heeft aangetoond dat het mogelijk is om KLK3, PCA3 en TMPRSS2-ERG 
mRNA te meten in perifere bloedmonsters van CRPC patiënten. De respons van 
deze markers op docetaxel behandeling is eveneens aangetoond.
Dit proefschrift laat de klinische toepassing zien van prostaatkanker biomarkers 
in zowel urine en bloed. De waarde van het rectaal toucher voorafgaand aan het 
afnemen van urine voor prostaatkanker biomarker analyse is hierin beschreven. 
Vervolgens is een risico stratificatie model voor hooggradig prostaatkanker 
ontwikkeld, gebaseerd op een moleculaire urinetest, die kan bijdragen in de 
klinische besluitvorming voor het verrichten van prostaatbiopten. Implementatie 
van deze risico score zou de kwaliteit van leven van mannen verdacht voor 
prostaatkanker kunnen verbeteren en gezondheidskosten kunnen reduceren. 
Tevens is aangetoond dat prostaat(kanker) specifieke biomarkers kunnen worden 
gemeten in het bloed van CRPC patiënten. Dit is mogelijk een belangrijke stap 
voorwaarts in de zoektocht naar betrouwbare markers voor therapierespons en 
overleving.
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deden! Kim, bedankt voor jouw creatieve oplossingsvermogen, inspanningen en 
mooie gesprekken. Sander, blijf oefenen met de bakjes als dat kan bij de IGZ. Ooit 
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en betrokkenheid bij de verschillende studies. Ook de patiënten die allemaal 
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125
Dankwoord Chapter 9
9
Harald en Thijs, homeboys! Het is een eer dat jullie op dit unieke moment naast 
mij staan als paranimfen. De oorsprong van onze vriendschap ligt in Arnhem en 
we zagen elkaar tijdens onze studententijd regelmatig in Groningen en Utrecht. 
Harald, samen in LenteBLIK, hardloopsessies in ommelanden en uiteraard vele 
avonden aan de bar. Thijs, onze gezamenlijke interesse in de Urologie kwam in 
Nijmegen weer bij elkaar, waarbij we ook in hetzelfde jaar werden aangenomen. 
Regelmatig met ook Sylvan vroegere tijden weer herbeleven is mooi. Bedankt 
voor jullie vriendschap.
Johan & Anneke, Michiel & Leonie (en Mees), heel erg bedankt voor jullie altijd 
oprechte interesse in mij en het werk dat mij bezig houdt. Dat de deur bij jullie 
altijd open staat waardeer ik enorm, bedankt!
Lieve mama en papa, bedankt voor jullie onvoorwaardelijke steun en interesse in 
alles wat ik doe. Met jullie enthousiasme compenseren jullie de momenten waar 
ik dat soms minder ben. En hoewel jullie me dat niet vaak zullen horen zeggen, 
zijn jullie voor mij van onschatbare waarde. Ik had me geen betere ouders kunnen 
wensen.
Lieve Jochem & Marieke (en Armin, Luna) en Nick, door de afstand zien we elkaar 
niet heel veel, maar dat maakt de momenten dat we elkaar zien extra speciaal. 
Misschien lijkt het soms vanzelfsprekend, maar voor mij is dat erg waardevol.
Lieve Heleen, jouw vertrouwen in mij betekent veel. De afgelopen jaren heb je 
me altijd gesteund in wat ik doe en heb je altijd begrip gehad voor de tijd die de 
opleiding en het promotie onderzoek in beslag neemt, ook al kon dat soms lastig 
zijn. Hou van jou!
126
LIST OF PUBLICATIONS
Cost-effectiveness of a new urinary biomarker-based risk score compared to 
standard of care in prostate cancer diagnostics – a decision analytical model 
Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Van Criekinge W, Van Neste L, 
Grutters JPC, Sedelaar JPM, van Oort IM
Accepted	for	publication	in	British	Journal	of	Urology	International	2017
Detection of high-grade prostate cancer using a urinary molecular 
biomarker-based risk score
Dijkstra Sǂ, Van Neste Lǂ, Hendriks RJǂ, Trooskens G, Cornel EB, Jannink SA, de 
Jong H, Hessels D, Smit FP, Melchers WJG, Leyten GHJM, de Reijke TM, Vergunst 
H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PFA, van Oort IM, Van 
Criekinge W, Schalken JA
ǂ These authors equally contributed to this work
European Urology 2016 Apr;70(5):740-8
The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide 
plus dutasteride therapy for patients with locally advanced or metastatic 
carcinoma of the prostate - a long-term follow-up comparison and quality of 
life analysis
Dijkstra S, Witjes WPJ, Roos EPM, Vijverberg PLM, Geboers ADH, Bruins JL, Smits 
GAHJ, Vergunst H, Mulders PFA
SpringerPlus 2016 May;5:653
Clinically useful diagnostic and prognostic biomarkers in prostate cancer
(Article in Dutch)
Dijkstra S, Mulders PFA, Schalken JA
Nederlands	Tijdschrift	voor	Oncologie	2016	July;13(5):164-170
Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in 
whole urine, urinary sediment and exosomes
Hendriks RJ, Dijkstra S, Jannink SA, Steffens MG, van Oort IM, Mulders PFA, 
Schalken JA
Clinical	Chemistry	and	Laboratory	Medicine	2016	Mar;54(3):483-92
127
List of publications Chapter 9
9
Validation of a new urine test for clinically significant prostate cancer 
(Article in Dutch)
Dijkstra Sǂ, Hendriks RJǂ, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, 
Melchers WJG, Leyten GHJM, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, 
Hulsbergen-van de Kaa CA, Mulders PFA, van Oort IM, Schalken JA
ǂ These authors equally contributed to this work
Tijdschrift	voor	Urologie	2016	Feb;6:34-43
Potential utility of cancer-specific biomarkers for assessing response to hormonal 
treatments in metastatic prostate cancer
Schalken JA, Dijkstra S, Baskin-Bey E, van Oort IM
Therapeutic	Advances	in	Urology	2014	Dec;6(6):245-52
KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear 
cell fraction from castration-resistant prostate cancer patients and response to 
docetaxel treatment
Dijkstra Sǂ, Leyten GHJMǂ, Jannink SA, de Jong H, Mulders PFA, van Oort 
IM, Schalken JA
ǂ These authors equally contributed to this work
The Prostate 2014 Sep;74(12):1222-30
Clinical use of novel urine and blood based prostate cancer biomarkers: a review
Dijkstra S, Mulders PFA, Schalken JA
Clinical Biochemistry 2014 Jul;47(10-11):889-96
Prostate cancer biomarker profiles in urinary sediments and exosomes
Dijkstra S, Birker IL, Smit FP, Leyten GHJM, de Reijke TM, van Oort IM, Mulders 
PFA, Jannink SA, Schalken JA
Journal of Urology 2014 Apr;191(4):1132-8
Personalized management in low-risk prostate cancer: the role of biomarkers
Dijkstra S, Hamid AR, Leyten GHJM, Schalken JA
Prostate Cancer 2012;2012:327104
Synchronous penile metastasis from a high-grade adenocarcinoma of the 
prostate
Dijkstra S, van der Heijden AG, Schaafsma HE, Mulders PFA
Case Reports in Urology 2012;2012:193787
128
A patient with bilateral testicular cancer (Article in Dutch)
Dijkstra S, Witjes JA
Nederlands	Tijdschrift	voor	Geneeskunde 2012;156(11):A3392
Book chapters
Biomarkers for prostate cancer
Dijkstra S, Hendriks RJ, Leyten GHJM, Mulders PFA, Schalken JA
Management of prostate cancer, Chapter 5. Springer 2017
Editors: M. Bolla and H. van Poppel
129
Curriculum Vitae Chapter 9
9
CURRICULUM VITAE
Siebren Dijkstra was born on the 6th of December 
1984 in Arnhem, the Netherlands. In 2003 he 
passed his Atheneum exam at the Thomas à 
Kempis/Arentheem College in Arnhem. After 
obtaining his propedeuse in Civil Engineering 
he started his Medicine study in 2004 at the 
University of Groningen. He performed his 
internships at the Deventer Hospital. Here his 
attention in the field of Urology was drawn. 
After a short internship visit at the department 
of Urology of the Guadalajara Civil Hospital in 
Mexico, he conducted his graduation research 
and clinical internship at the Urology department 
of the Radboud University Medical Center 
Nijmegen from 2010 until 2011. In 2011 he did his final internship Emergency 
Surgery and Traumatology at the Groote Schuur Hospital in Cape Town and 
obtained his medical degree. 
Consequently, he proceeded to work as a resident at the department of Urology 
of the Radboud University Medical Center Nijmegen. In 2012 he started his PhD 
research under the supervision of prof. dr. J.A. Schalken, prof. dr. P.F.A. Mulders and 
dr. I.M. van Oort, focusing on the identification and understanding of biomarkers 
in the diagnosis and treatment of prostate cancer. During the two years that 
he worked as a PhD candidate he attended several national and international 
conferences where he presented most of his work and he supervised two medical 
students during their scientific internships.
In January 2014 he started the Urology residency training program at the 
department of General Surgery at the Canisius Wilhelmina Hospital (CWZ) in 
Nijmegen (supervisors: dr. C. Rosman and dr. F. Polat). Currently, Siebren Dijkstra 
is working at the department of Urology at the Radboud University Medical 
Center Nijmegen (supervisor: prof. dr. J.A. Witjes), where he continues his career 
as a Urology resident.

